[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 563
1. Uramoto H, Yamada S, Hanagiri T: Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer. J Cardiothorac Surg; 2010;5:92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer.
  • BACKGROUND: adenosquamous carcinoma (ADSQ) of non-small cell lung cancer (NSCLC) is a rare disease and the biological behavior and clinicopathological characteristics have not yet been thoroughly described.
  • ADSQ was found less frequently in males than squamous cell carcinoma (SQ).
  • ADSQ was found more frequently in older patients, with advanced stage, advanced T status, and lymph node metastases than adenocarcinoma (AD).
  • The proportion with coexistent double cancer of AD, SQ, and ADSQ were 21.1, 17.6, and 45.5%, respectively.
  • CONCLUSIONS: In this study, cases with ADSQ showed no significantly prognostic difference in comparison to AD and SQ.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1996 Apr;109(4):989-94 [8635382.001]
  • [Cites] Cancer Invest. 1993;11(6):641-51 [8221196.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):861-5 [9625833.001]
  • [Cites] Scand Cardiovasc J. 1999;33(1):29-32 [10093856.001]
  • [Cites] Respir Med. 2006 Dec;100(12):2073-84 [17056245.001]
  • [Cites] Ann Thorac Surg. 2007 Aug;84(2):702-7 [17643676.001]
  • [Cites] Med Oncol. 2009;26(1):27-31 [18483884.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1289-98 [10751354.001]
  • [Cites] Jpn J Cancer Res. 1999 Nov;90(11):1244-7 [10622536.001]
  • [Cites] Chest. 2000 Feb;117(2):374-9 [10669677.001]
  • [Cites] Ann Thorac Surg. 2003 Jun;75(6):1740-4 [12822609.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:219-42 [4088299.001]
  • [Cites] Ann Thorac Surg. 1987 Nov;44(5):462-6 [3675050.001]
  • [Cites] Am Rev Respir Dis. 1990 Jul;142(1):19-23 [2368969.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):649-54 [1985759.001]
  • [Cites] Am J Clin Pathol. 1992 May;97(5):678-85 [1575214.001]
  • [Cites] Ann Thorac Surg. 1993 Mar;55(3):593-6 [8452418.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • (PMID = 21034441.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit
  • [Other-IDs] NLM/ PMC2987925
  •  go-up   go-down


2. Farah-Klibi F, Ben Rejeb M, Salah RB, Najeh N, Zaouche A, Ben Jilani S, Zermani R: [Adenosquamous cell carcinoma of the gallbladder]. Gastroenterol Clin Biol; 2008 Jun-Jul;32(6-7):632-4
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenosquamous cell carcinoma of the gallbladder].
  • [Transliterated title] Carcinome adénosquameux primitif de la vésicule biliaire.
  • [MeSH-major] Carcinoma, Adenosquamous. Gallbladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556164.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down


3. Wang J, Wang FW, Lagrange CA, Hemstreet GP: Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate. Rare Tumors; 2010;2(3):e47

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate.
  • The aim of the present study was to examine the epidemiology, natural history, treatment and long-term survival of patients with adenosquamous cell carcinoma of the prostate.
  • A total of 25 patients with adenosquamous cell carcinoma of the prostate were identified during the study period.
  • Twenty percent of study subjects presented with metastatic disease.
  • Adenosquamous cell carcinoma is a rare aggressive subtype of prostate cancer with poor cancer specific survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139962.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994527
  • [Keywords] NOTNLM ; ASCC / SEER / adenosquamous cell carcinoma / and end results / cancer specific survival / epidemiology / prostate / surveillance
  •  go-up   go-down


Advertisement
4. Martinez JM, Stephens LC, Jones LA: Long-term effects of neonatal exposure to hydroxylated polychlorinated biphenyls in the BALB/cCrgl mouse. Environ Health Perspect; 2005 Aug;113(8):1022-6
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mice treated with OH-PCB-30 (200 microg/day) or 17beta-estradiol (5 microg/day) showed similar increased incidences of cervicovaginal (CV) tract carcinomas (43% and 47%, respectively).
  • In addition, when mice were treated with OH-PCBs as a mixture, a change in the type of CV tract tumor was observed, shifting from predominantly squamous cell carcinomas to adenosquamous cell carcinoma.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 1999 Jan;107(1):45-51 [9872716.001]
  • [Cites] Chemosphere. 1998 Oct-Nov;37(9-12):1845-53 [9828313.001]
  • [Cites] Toxicol Lett. 1998 Dec 28;102-103:331-5 [10022274.001]
  • [Cites] Environ Health Perspect. 1999 Aug;107 Suppl 4:639-49 [10421775.001]
  • [Cites] Sci Total Environ. 1999 Aug 15;233(1-3):141-61 [10492903.001]
  • [Cites] J Natl Cancer Inst. 1963 Aug;31:425-55 [14046632.001]
  • [Cites] Toxicology. 2005 Mar 30;208(3):377-87 [15695023.001]
  • [Cites] Toxicol Sci. 2005 Mar;84(1):49-62 [15601674.001]
  • [Cites] J Natl Cancer Inst. 1976 Nov;57(5):1057-62 [187788.001]
  • [Cites] J Natl Cancer Inst. 1976 Nov;57(5):1185-9 [187796.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jan;101(1):1-5 [576195.001]
  • [Cites] Environ Res. 1978 Jul;16(1-3):123-30 [98321.001]
  • [Cites] Arch Toxicol. 1978 Dec 28;41(3):179-86 [104695.001]
  • [Cites] Cancer Res. 1979 Jul;39(7 Pt 1):2560-7 [445458.001]
  • [Cites] J Pediatr. 1984 Aug;105(2):315-20 [6431068.001]
  • [Cites] Arch Environ Contam Toxicol. 1985 Jan;14(1):51-7 [3919656.001]
  • [Cites] Environ Health Perspect. 1985 May;60:35-9 [2992924.001]
  • [Cites] IARC Sci Publ. 1985;(65):107-17 [4086078.001]
  • [Cites] Environ Res. 1986 Oct;41(1):14-22 [3093216.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1289-98 [10751354.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):568-74 [11251983.001]
  • [Cites] Environ Toxicol Chem. 2001 Feb;20(2):351-8 [11351435.001]
  • [Cites] Environ Health Perspect. 2001 Jul;109(7):739-47 [11485874.001]
  • [Cites] Arch Environ Contam Toxicol. 2002 Jan;42(1):105-17 [11706375.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1560-5 [12496044.001]
  • [Cites] Environ Sci Technol. 2003 Mar 1;37(5):832-9 [12666909.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):389-94 [12676588.001]
  • [Cites] Cancer. 2003 May 1;97(9):2196-202 [12712471.001]
  • [Cites] Environ Health Perspect. 2004 Aug;112(11):1208-12 [15289169.001]
  • [Cites] N Engl J Med. 1971 Apr 15;284(15):878-81 [5549830.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1974 Sep;9(1):85-95 [4216060.001]
  • [Cites] J Steroid Biochem. 1975 May;6(5):673-6 [1186250.001]
  • [Cites] Cancer Res. 1977 Jan;37(1):67-75 [830422.001]
  • [Cites] Chem Biol Interact. 1986 Sep;59(2):173-84 [3769051.001]
  • [Cites] Mol Pharmacol. 1988 Jan;33(1):120-6 [3122017.001]
  • [Cites] Arch Environ Health. 1987 Nov-Dec;42(6):333-9 [3125795.001]
  • [Cites] Am J Epidemiol. 1989 Feb;129(2):395-406 [2492144.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7677-81 [2174729.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 20;86(8):589-99 [8145274.001]
  • [Cites] J Cardiovasc Surg (Torino). 1994 Dec;35(6):543-7 [7698972.001]
  • [Cites] Early Hum Dev. 1995 Apr 14;41(2):111-27 [7601016.001]
  • [Cites] Chemosphere. 1995 Aug;31(4):3017-23 [7552046.001]
  • [Cites] Arch Environ Contam Toxicol. 1995 Oct;29(3):334-43 [7487157.001]
  • [Cites] Environ Health Perspect. 1994 May;102(5):464-9 [8593850.001]
  • [Cites] Environ Health Perspect. 1995 Sep;103 Suppl 6:117-22 [8549457.001]
  • [Cites] Cancer Causes Control. 1995 Nov;6(6):551-66 [8580305.001]
  • [Cites] Environ Health Perspect. 1995 Oct;103 Suppl 7:141-5 [8593861.001]
  • [Cites] Biol Reprod. 1997 May;56(5):1147-57 [9160713.001]
  • [Cites] Environ Health Perspect. 1997 Apr;105 Suppl 3:577-81 [9167998.001]
  • [Cites] Toxicol Appl Pharmacol. 1997 Jul;145(1):111-23 [9221830.001]
  • [Cites] Environ Health Perspect. 1997 Oct;105(10):1030-2 [9349835.001]
  • [Cites] Toxicol Appl Pharmacol. 1997 Nov;147(1):93-100 [9356311.001]
  • [Cites] Ecotoxicol Environ Saf. 1997 Dec;38(3):281-5 [9469881.001]
  • [Cites] Toxicol Sci. 1998 Jan;41(1):62-76 [9520342.001]
  • [Cites] Chemosphere. 1997 Feb;34(4):835-48 [9569946.001]
  • [Cites] Am J Ind Med. 1998 Jul;34(1):6-14 [9617382.001]
  • [Cites] J Pediatr. 1999 Jan;134(1):33-41 [9880446.001]
  • (PMID = 16079073.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 16652
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; DFC2HB4I0K / Polychlorinated Biphenyls
  • [Other-IDs] NLM/ PMC1280343
  •  go-up   go-down


5. Gu MJ, Choi JH, Park WK, Chang JC, Kim HJ: [Primary adenosquamous carcinoma of the liver: a case report]. Korean J Hepatol; 2005 Mar;11(1):86-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenosquamous carcinoma of the liver: a case report].
  • Primary adenosquamous cell carcinoma of the liver, a variant of cholangiocarcinoma is very rare disease and its prognosis is known to be very poor.
  • We describe here a case of primary adenosquamous carcinoma of the liver.
  • Needle biopsy of the mass was done and the histologic diagnosis was cholangiocarcinoma.
  • Microscopically, the tumor was composed of both adenocarcinoma and squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Liver Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788889.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


6. Song HG, Yoo KS, Ju NR, Park JC, Jung JO, Shin WG, Moon JH, Kim JP, Kim KO, Park CH, Hahn T, Park SH, Kim JH, Lee IJ, Min SK, Park CK: [A case of adenosquamous carcinoma of the papilla of Vater]. Korean J Gastroenterol; 2006 Aug;48(2):132-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adenosquamous carcinoma of the papilla of Vater].
  • Adenosquamous carcinoma of the papilla of Vater is a rare tumor and only a few cases have been reported so far.
  • Here, we report a case of adenosquamous carcinoma in a 76-year-old male who presented with jaundice and right upper quadrant abdominal pain.
  • Histopathological inspection of the biopsied specimens from mass showed adenosquamous cell carcinoma of the papilla of Vater.
  • This is the first case report on adenosquamous carcinoma of the papilla of Vater in Korea.
  • [MeSH-major] Ampulla of Vater / pathology. Carcinoma, Adenosquamous / diagnosis
  • [MeSH-minor] Aged. Cell Differentiation. Humans. Immunohistochemistry. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929159.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


7. Chan PK, Ho WC, Yu MY, Pong WM, Chan AC, Chan AK, Cheung TH, Wong MC, To KF, Ng HK: Distribution of human papillomavirus types in cervical cancers in Hong Kong: current situation and changes over the last decades. Int J Cancer; 2009 Oct 1;125(7):1671-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among cervical squamous cell carcinoma (SCC) cases diagnosed over the past 10 years, HPV16 was most commonly found (61.2%), followed by HPV18 (17.7%), HPV52 (14.7%) and HPV58 (9.9%), whereas adeno/adenosquamous cell carcinoma was dominated by HPV18 (56.3%) and HPV16 (50.0%).
  • Vaccines comprising HPV16/18 cover 62.6% of SCC and 93.8% of adeno/adenosquamous carcinoma in Hong Kong, and inclusion of HPV52 and HPV58 can increase the coverage by 18.4% for SCC and 4.1% for adeno/adenosquamous cell carcinoma.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / virology. Adult. Aged. Asian Continental Ancestry Group / statistics & numerical data. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / virology. Chi-Square Distribution. Female. Hong Kong / epidemiology. Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18. Humans. Middle Aged. Papillomavirus Vaccines / administration & dosage. Precancerous Conditions / epidemiology. Precancerous Conditions / virology


8. Akcali Z, Ozyilkan O, Sakalli H, Bal N, Noyan T: Gallbladder adenosquamous cell carcinoma: report of two cases. Acta Gastroenterol Belg; 2005 Oct-Dec;68(4):440-2
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallbladder adenosquamous cell carcinoma: report of two cases.
  • Adenocarcinoma is the usual histological presentation of the very rare gallbladder carcinoma.
  • Adenosquamous cell carcinoma accounts for less than 3.5% of gallbladder carcinomas, and is characterised by invasive growth, a reduced tendency for lymph node metastasis, an increased tendency for hepatic infiltration or liver metastasis, and a poorer prognosis than adenocarcinoma.
  • Adenosquamous carcinoma of the gallbladder was diagnosed on the post-operative pathological specimen.
  • Cytology specimens obtained with an endoscopic retrograde cholangiopancreatography (ERCP) procedure revealed a malignant epithelial tumour.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Gallbladder Neoplasms / pathology. Gallbladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432998.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Uramoto H, Yamada S, Hanagiri T: Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung. Anticancer Res; 2010 Nov;30(11):4717-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung.
  • The aim of this study was to detect the deltaNp63 expression in the squamous carcinoma component of adenosquamous carcinoma and evaluate its usefulness as a specific squamous carcinoma marker.
  • PATIENTS AND METHODS: Immunohistochemistry was used to analyze the protein expression of deltaNp63 and high molecular weight cytokeratin in paraffin-embedded tumor samples from 17 patients with well-characterized adenosquamous carcinoma.
  • It was easy to discriminate the squamous carcinoma and adenocarcinoma components in all tumors.
  • CONCLUSION: These findings indicated that the deltaNp63 status was useful for distinguishing squamous carcinoma from adenocarcinoma in formalin-postfixed adenosquamous carcinoma specimens.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Adenosquamous / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115930.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


10. Gatlez J, Hendlisz A, Legendre H, Sirtaine N, Debroux S, Awada A: [Colorectal epidermoid carcinoma and paraneoplastic hypercalcemia]. Acta Clin Belg; 2007 Nov-Dec;62(6):433-7
Genetic Alliance. consumer health - Epidermoid Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colorectal epidermoid carcinoma and paraneoplastic hypercalcemia].
  • [Transliterated title] Carcinome épidermoïde colorectal et hypercalcémie paranéoplasique.
  • The squamous cell carcinoma and the adenosquamous cell carcinoma of the colon and rectum are not well know and rare tumours.
  • We report a case of squamous cell carcinoma of the recto-sigmoid who relapses in the liver after surgery of the primary tumour with paraneoplasic hypercalcaemia.
  • We will discuss the pathogenesis, prognosis, associated conditions, clinical features and treatment strategies of squamous and adenosquamous cell carcinoma of the colon and the rectum.
  • [MeSH-major] Carcinoma, Adenosquamous / secondary. Hypercalcemia / etiology. Paraneoplastic Syndromes / etiology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18351188.001).
  • [ISSN] 1784-3286
  • [Journal-full-title] Acta clinica Belgica
  • [ISO-abbreviation] Acta Clin Belg
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


11. Fujiu K, Sakuma H, Shio Y, Suzuki H, Mori M: [A case of non-Hodgkin's lymphoma after chemotherapy for cancer of unknown origin]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1907-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography(CT)scans showed a swelling of the superior mediastinal lymph node and a tumor of the right lobe of thyroid gland.
  • Pathological findings of the lymph node showed adenosquamous cell carcinoma, but no malignant lesion was found in the thyroid gland.
  • Post-operative systemic survey failed to identify the origin of the adenosquamous cell carcinoma.
  • Seven months later, CT and positron emission tomography revealed swelling of the mediastinal lymph nodes and a tumor in the left abdominal tumor.
  • An open biopsy of the abdominal tumor demonstrated non-Hodgkin's lymphoma, mature B cell type, follicular lymphoma, grade 1.
  • Radiotherapy was done for the malignant lymphoma, and radiochemotherapy for the mediastinal lymph nodes.
  • Seven months later, the patient died of systemic metastases of the adenosquamous cell carcinoma.
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Biopsy. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Combined Modality Therapy. Humans. Male. Tomography, X-Ray Computed. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011340.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Yokota H, Matoba M, Tonami H, Hasegawa T, Saito H, Kurose N: Imaging findings in primary adenosquamous carcinoma of the liver: a case report. Clin Imaging; 2007 Jul-Aug;31(4):279-82
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging findings in primary adenosquamous carcinoma of the liver: a case report.
  • Adenosquamous cell carcinoma is characterized by both squamous and glandular components, and is a rare disease of the liver that is the subject of few reports in the literature.
  • We present a case in which the imaging findings on CT, MRI, and hepatic arteriography, as well as pathological correlation of the tumor and the clinical history, aided in including this entity in the differential diagnosis.
  • [MeSH-major] Carcinoma, Adenosquamous / radiography. Liver Neoplasms / radiography. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17599625.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Suzuki T, Suzuki T, Shinoda M, Takashi H, Yamaguchi H, Murayama M, Kamiya T, Morise K, Tashiro K, Kimura M, Yamagishi S, Ando T, Goto H: [An autopsy case of colon cancer associated ulcerative colitis complicated focal squamous cell carcinoma]. Nihon Shokakibyo Gakkai Zasshi; 2007 May;104(5):684-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An autopsy case of colon cancer associated ulcerative colitis complicated focal squamous cell carcinoma].
  • At autopsy, the histological examination showed many mucinous adenocarcinoma and signet ring cell carcinoma with dysplasia.
  • There were also some areas of squamous cell carcinoma with squamous metaplasia and dysplasia far from rectum.
  • Squamous cell carcinoma and adenosquamous cell carcinoma of the colon are rare complications of ulcerative colitis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Colitis, Ulcerative / complications. Colonic Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Adenosquamous / pathology. Carcinoma, Signet Ring Cell / pathology. Female. Humans. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17485949.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Otrock ZK, Mahfouz RA, Salem ZM: Four primary tumors of lung, bladder, prostate, and breast in a male patient. South Med J; 2005 Sep;98(9):946-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is a case of both synchronous and metachronous primary malignant neoplasms occurring in four different organs.
  • Immunohistochemical stains showed tumor cell nuclei to be negative for p53 over-expression.
  • The tumors included an adenosquamous cell carcinoma of the lung, transitional cell carcinoma of the urinary bladder, and adenocarcinomas of the prostate and the breast.
  • We also review the medical literature for the possible causes of multiple primary malignant neoplasms.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma / complications. Lung Neoplasms / complications. Prostatic Neoplasms / complications. Urologic Neoplasms / complications
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystectomy. Fatal Outcome. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mastectomy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Radiotherapy, Adjuvant. Shock, Septic / complications. Spinal Neoplasms / complications. Spinal Neoplasms / diagnosis. Spinal Neoplasms / secondary. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217994.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Arenas Prat M, Rovirosa A, Sabater S, Ameijide A, Henríquez I, Servitja S, Cabezas I, Mur E, Gumà J: Experience with endometrial carcinoma (EC): A population-based study in Tarragona Province (Spain). J Clin Oncol; 2009 May 20;27(15_suppl):e16550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience with endometrial carcinoma (EC): A population-based study in Tarragona Province (Spain).
  • Multivariate analysis of disease-free survival (DFS), overall survival (OS), adjuvant RT, RT toxicity (RTOG), prognostic factors for survival, and the distance in Km to the RT Units.
  • Pathology: endometrioid 74.5%, papillary 3.9%, serous 3.4%, clear-cell 2.2%, squamous cell 3%, adenosquamous 1.3%, mixed 3.9%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960813.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tsubamoto H, Wada R, Kanazawa R, Komori S, Maeda H, Hirota S, Adachi S: Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16518

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma.
  • : e16518 Background: Adenocarcinoma (including adenosquamous carcinoma) of the uterine cervix has a tendency to early lymph node metastasis and is resistant to radiation therapy, thus results in poor prognosis compared with squamous cell carcinoma.
  • Neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) for bulky cervical adenocarcinoma seems to be an alternative therapy to primary radiation.
  • Eligible criteria were as follows: Histologically diagnosed cervical adeno or adenosquamous carcinoma with FIGO stage IB2-IVA, Age < or equal to 75, PS 0-2, given informed consent.
  • RESULTS: Enrolled patients: 22 (1998-2006), Age: median 51 (33-75), FIGO stage: IB2 (9), IIA-IIB (8), IIIB (3), IVA (2), adeno/adenosquamous: 16/6.
  • 16 of 17 received RH, and no residual malignant cells were found pathologically (pCR) in 3.
  • CONCLUSIONS: TACE with cisplatin and dose dense paclitaxel in the neoadjuvant setting is feasible and effective for cervical adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Sugio K, Nagashima A, Nakanishi R, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Takenoyama M, Hanagiri T, Yasumoto K: Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC).
  • The primary endpoint was compliance, and secondary endpoints were the disease free survival (DFS) and toxicity.
  • The patients were stratified by gender, histology (adenoca vs. non-adenoca) and disease stage.
  • The histologic types included adenocarcinoma (n=51), squamous cell carcinoma (n=18), large cell carcinoma (n=5), and adenosquamous cell carcinoma (n=1).
  • Twenty-one of 39 pts (54%) in arm A and 25 of 36 pts (69%) in arm B completed 8 cycles, and 59% in arm A and 81% in arm B completed ≥6 cycles.
  • Up to 12/2008, 11 of 39 pts in arm A and 13 of 36 pts in arm B had recurrent disease, but no significant difference was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963358.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. McCormack M, Ledermann JA, Hall-Craggs MA, Symonds RP, Warwick V, Simonds H, Fernando I, Hackshaw A: A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5586

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Baseline characteristics were: median age at diagnosis 43 yrs (23-71); 74% squamous-, 20% adeno- and 6% adenosquamous carcinomas; FIGO stage IB2 (11%), II (50%), III (33%), IV (6%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962391.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Bjerregaard JK, Schønnemann KR, Jensen HA, Vestermark LW, Hansen TP, Pfeiffer P: Biweekly cetuximab and irinotecan as second-line therapy to patients with platinium-resistant gastroesophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All pts had histologically confirmed GE cancer (adeno- or squamous cell carcinoma) and all pts had previously received first line platinum based therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962695.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Vasiljevic M, Pazin V, Dzatic O, Jeremic D: Primary fallopian tube carcinoma in a 51-year-old postmenopausal woman--case report. Eur J Gynaecol Oncol; 2007;28(6):531-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube carcinoma in a 51-year-old postmenopausal woman--case report.
  • The case of a 51-year-old woman with a primary carcinoma of the left fallopian tube is presented.
  • Histopathological examination revealed primary adenosquamous cell carcinoma of the fallopian tube.
  • [MeSH-major] Fallopian Tube Neoplasms / diagnosis. Postmenopause

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179157.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Aréchaga-Ocampo E, Pereira-Suárez AL, del Moral-Hernández O, Cedillo-Barrón L, Rodríguez-Sastre MA, Castillo-Alvarez A, López-Bayghen E, Villegas-Sepúlveda N: HPV+ cervical carcinomas and cell lines display altered expression of caspases. Gynecol Oncol; 2008 Jan;108(1):10-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HPV+ cervical carcinomas and cell lines display altered expression of caspases.
  • We analyzed here, the basal expression of precursors of apoptotic Caspases in normal cervical epithelium, HPV+ cervical tumor samples and HPV+ tumor-derived cell lines.
  • METHODS: Expression of initiator and effector Caspases was analyzed by immunochemistry in normal cervical epithelium and three types of cervical tumors (squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma) whereas expression of Caspases in HeLa, SiHa and CaSki cells was by immunofluorescence, Western blot and RT-PCR.
  • RESULTS: Expression of Caspases 3 and 9 was undetectable in adenocarcinoma and adenosquamous cell carcinoma, respectively.
  • Whereas in squamous cell carcinoma, the expression of Caspases was similar those observed in normal samples.
  • We did not observe an effect of the E6/E7 oncogenes on the expression of Caspases in C33-A cell.
  • CONCLUSION: Our results showed a differential expression of several Caspases in carcinoma samples and cell lines, suggesting multiple alterations of the Caspase pathways in cervical cancer.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenocarcinoma / virology. Blotting, Western. Carcinoma, Adenosquamous / enzymology. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Cell Line, Tumor. Female. Fluorescent Antibody Technique. HeLa Cells. Human papillomavirus 16. Human papillomavirus 18. Humans. Immunohistochemistry. Isoenzymes / biosynthesis. Paraffin Embedding. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936882.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 3.4.22.- / Caspases
  •  go-up   go-down


22. Dong QG, Han BH, Huang JS, Yang LM, Huang J, Zhao CY, Lu LQ: [Analysis of EGFR mutations in 176 cases of non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2006 Sep;28(9):686-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of EGFR mutations in 176 cases of non-small cell lung cancer].
  • OBJECTIVE: To analyze the incidence and profile of mutations in epidermal growth factor receptor (EGFR) in Chinese patients with non-small cell lung cancer (NSCLC).
  • The EGFR mutations were more frequent in female patients than male ones, in adenocarcinoma and adenosquamous cell carcinoma versus cancer of other histologies.
  • CONCLUSION: EGFR mutation is a tumor-specific somatic abnormality.
  • These mutations are more frequently detected in female, adenocarcinoma and adenosquamous cell carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adult. Aged. Amino Acid Sequence. Base Sequence. Carcinoma, Squamous Cell / genetics. Codon. DNA Mutational Analysis. Exons. Female. Gene Deletion. Humans. Male. Middle Aged. Mutation, Missense. Sex Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274376.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Codon; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


23. Kashiwazaki M, Takeda Y, Hasuike Y, Masuda N, Ikenaga M, Hirao M, Fujitani K, Mishima H, Sawamura T, Nakamori S, Takeda M, Mano Y, Tsujinaka T: [A case of successful resection for recurrent intraductal papillary mucinous adenocarcinoma]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1863-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successful resection for recurrent intraductal papillary mucinous adenocarcinoma].
  • A histopathological study revealed invasive adenocarcinoma and the negative margin of the pancreatic duct.
  • Recurrent IPMN consisted of adenosquamous cell carcinoma.
  • She currently is alive without evidence of disease at 3 years from the second resection.
  • Recurrent disease in the residual pancreas suggests that a long-term surveillance is critical.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Pancreatic Ducts. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315964.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Teramoto N, Nishimura R, Saeki T, Nogawa T, Hiura M: Adenoid basal carcinoma of the uterine cervix: report of two cases with reference to adenosquamous carcinoma. Pathol Int; 2005 Jul;55(7):445-52
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid basal carcinoma of the uterine cervix: report of two cases with reference to adenosquamous carcinoma.
  • Adenoid basal carcinoma (ABC) of the uterine cervix is a rare neoplasm with excellent prognosis.
  • Differential diagnosis between ABC and an ABC-like lesion of adenosquamous cell carcinoma (ASC) of the cervix is important due to their contrasting prognosis.
  • The two ABC were incidentally found in the uterine cervix of 69-year-old and 59-year-old Japanese women due to cervical intraepithelial neoplasia grade 3 and to squamous cell carcinoma, respectively.
  • An ABC-like lesion was defined as basaloid cell nests simulating ABC, but with some features indicating malignant potential.
  • However, the differential diagnosis was sometimes difficult because two of seven ABC-like lesions were originally diagnosed as ABC.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Basal Cell / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Keratin-8. Keratins / analysis. Ki-67 Antigen / analysis. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982222.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / KRT8 protein, human; 0 / Keratin-7; 0 / Keratin-8; 0 / Ki-67 Antigen; 68238-35-7 / Keratins
  •  go-up   go-down


25. Satoh M, Wakabayashi O, Araya Y, Jinushi E, Yoshida F: [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor]. Nihon Kokyuki Gakkai Zasshi; 2009 Sep;47(9):798-804
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autopsy case of von Recklinghausen's disease associated with lung cancer, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor].
  • A 58-year-old man with von Recklinghausen's disease was admitted for further investigation of right chest pain.
  • Chest X-ray revealed multiple emphysematous bullae in both lungs and a tumor shadow in the right upper lobe.
  • The tumor was diagnosed as a non-small-cell lung cancer with direct invasion to the adjacent rib.
  • Autopsy revealed multiple emphysematous bullae, poorly differentiated adenosquamous cell carcinoma of the lung, gastrointestinal stromal tumor of the stomach, and duodenal carcinoid tumor.
  • This case suggests the possibility that von Recklinghausen's disease associated with emphysematous bullae is a risk factor for lung cancer.
  • It has also been suggested that the genetic abnormality responsible for von Recklinghausen's disease increases the risk for various types of malignancy.
  • Although von Recklinghausen's disease is reportedly associated with various malignant tumors, it is quite rare for von Recklinghausen's disease to be associated with triple non-neurogenic tumors.
  • Careful observation is mandatory for patients with von Recklinghausen's disease.
  • [MeSH-major] Autopsy. Carcinoid Tumor / etiology. Carcinoma, Adenosquamous / etiology. Duodenal Neoplasms / etiology. Gastrointestinal Stromal Tumors / etiology. Lung Neoplasms / etiology. Neoplasms, Multiple Primary. Neurofibromatosis 1 / complications
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Pulmonary Emphysema / complications. Pulmonary Emphysema / diagnosis. Pulmonary Emphysema / pathology. Risk Factors

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827584.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


26. Morinaga R, Matsunaga N, Iwata A, Kishi K, Tokimatsu I, Nagai H, Kadota J: [A case of diaphragmatic paralysis caused by herpes zoster after anticancer chemotherapy]. Nihon Kokyuki Gakkai Zasshi; 2007 Feb;45(2):166-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 61-year-old woman who had been followed up after resection of lung cancer (adenosquamous cell carcinoma), was admitted to our hospital because of recurrence.
  • [MeSH-minor] Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / surgery. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Lymph Node Excision. Middle Aged. Pneumonectomy. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - paralysis.
  • MedlinePlus Health Information. consumer health - Shingles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352174.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


27. Tanaka T, Sekimura A, Tanaka H, Tonegawa K, Ogawa K, Haneda H: [Gallbladder metastasis of large cell lung cancer]. Kyobu Geka; 2009 Nov;62(12):1069-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gallbladder metastasis of large cell lung cancer].
  • A man, who received right upper lobectomy of the lung due to stage IIB large cell carcinoma 7 and half years ago, visited our hospital complaining of right upper abdominal pain.
  • Pathological diagnosis was adenosquamous cell carcinoma After 1 year and 4 months later, left adrenal gland tumor was found by CT scan, and the surgery was conducted.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Gallbladder Neoplasms / secondary. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894573.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Sugimoto Y, Semba H, Fujii S, Furukawa E, Kurano R: [Clinical analysis of primary lung cancer with a thin-walled cavity to explain the mechanism of thin-walled cavity formation]. Nihon Kokyuki Gakkai Zasshi; 2007 Jun;45(6):460-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, there were 5 cases of adenocarcinoma, 2 of squamous cell carcinoma, and 1 of adenosquamous cell carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Squamous Cell / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17644941.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


29. Xie LP, Qin J, Zheng XY, Shen HF, Chen ZD, Cai SL, Zhang ZG, Ding W, Ren GP, Wang LJ, Yu XR: [Age and pathological features of 481 prostate cancer patients]. Zhonghua Nan Ke Xue; 2005 Jun;11(6):428-30
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty cases (8.3%) were microcarcinoma (< 1 cm), and 20 cases (4.2%) incidental carcinoma.
  • Of the total number, 473 cases (98.1%) were pathologically diagnosed as adenocarcinoma, 1 endometrioid adenocarcinoma, 1 squamous cell carcinoma, 1 signet ring cell carcinoma, 1 adenosquamous cell carcinoma, 1 small cell carcinoma, 1 mucinous adenocarcinoma, 1 adenoid cystic carcinoma, and 1 transitional cell carcinoma.
  • CONCLUSION: Prostate cancer commonly develops in men over 65 years, and adenocarcinoma is the most common histological type.
  • The disease has become a major malignant tumor to endanger elderly males.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Age of Onset. Aged. Aged, 80 and over. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999486.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


30. Kobashi Y, Mouri K, Fukuda M, Yoshida K, Miyashita N, Niki Y, Nakata M, Mikio O: [A case of pulmonary adenosquamous cell carcinoma with thin-wall cavities]. Nihon Kokyuki Gakkai Zasshi; 2005 Jan;43(1):59-62
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pulmonary adenosquamous cell carcinoma with thin-wall cavities].
  • A histological diagnosis of pulmonary adenocarcinoma was obtained by bronchoscopic examination, and he was transferred to the Department of Thoracic Surgery where a right upper lobectomy was performed.
  • Most of the surrounding cavity consisted of the components of a well differentiated squamous cell carcinoma with keratinization and slightly different components of a poorly differentiated adenocarcinoma with mucous production.
  • The final diagnosis was pulmonary adenosquamous cell carcinoma and the postoperative histological classification was T2N2M0 (Stage 3A) because of metastasis to the lymph nodes (#4 and #11).
  • Although squamous cell carcinoma has been reported to be the histological type, tending to form thin-wall cavities among patients with lung cancer reported to be squamous cell carcinoma, recently an increasing number of such cavities have been reported among patients with pulmonary adenocarcinoma.
  • Herein, we have reported a rare case of histological diagnosis of pulmonary adenosquamous cell carcinoma with cavity formation.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lung / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15704455.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Niibe Y, Kenjo M, Onishi H, Ogawa Y, Kazumoto T, Ogino I, Tsujino K, Harima Y, Takahashi T, Anbai A, Tsuchida E, Toita T, Takemoto M, Yamashita H, Hayakawa K: High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in Japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006-2007 (study of JASTRO 2006-2007). Jpn J Clin Oncol; 2010 Aug;40(8):795-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in Japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006-2007 (study of JASTRO 2006-2007).
  • OBJECTIVE: The current study was a retrospective questionnaire survey of stage IIIb adenocarcinoma of the uterine cervix treated with high-dose-rate intracavitary brachytherapy combined with external beam radiation therapy in Japan aimed to investigate the optimal dose on the basis of the biological effective dose and prognostic factors.
  • METHODS: Between 1990 and 2000, 61 patients with stage IIIb adenocarcinoma of the uterine cervix underwent high-dose-rate intracavitary brachytherapy combined with external beam radiation therapy in 19 major hospitals in Japan.
  • Fifty had only adenocarcinoma components and 11 had adenosquamous cell carcinoma components.
  • Stratified by histopathology, the 5-year overall survival rate was 22.1% for adenocarcinoma and 13.6% for adenosquamous cell carcinoma (P = 0.43).
  • CONCLUSIONS: The 5-year overall survival rate of stage IIIb adenocarcinoma of the uterine cervix in this retrospective questionnaire survey was 20.2%.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Carcinoma, Adenosquamous / radiotherapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Population Surveillance. Prognosis. Radiotherapy Dosage. Retrospective Studies. Surveys and Questionnaires. Survival Rate. Treatment Failure

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20444747.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


32. Niibe Y, Hayakawa K, Kanai T, Tsunoda S, Arai M, Jobo T, Kuramoto H, Unno N: Optimal dose for stage IIIB adenocarcinoma of the uterine cervix on the basis of biological effective dose. Eur J Gynaecol Oncol; 2006;27(1):47-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal dose for stage IIIB adenocarcinoma of the uterine cervix on the basis of biological effective dose.
  • PURPOSE: Prognosis of uterine cervical adenocarcinoma in locally advanced stage treated with radiation therapy has been considered to be much worse than that of squamous cell carcinoma because the optimal dose for the former one has not been determined.
  • Thus, the current study was performed to investigate the optimal dose for Stage IIIB, locally advanced stage, adenocarcinoma of the uterine cervix on the basis of the biological effective dose (BED).
  • METHODS: One-hundred and seventy-nine patients with Stage IIIB carcinoma of the uterine cervix were treated with curative intended therapy at Kitasato University Hospital between 1976 and 2000.
  • Out of them, 13 patients had an adenocarcinoma component in pathological findings.
  • Nine patients were diagnosed with adenocarcinoma and four patients were diagnosed with adenosquamous cell carcinoma.
  • CONCLUSION: The current study suggested that the optimal dose for Stage IIIB adenocarcinoma of the uterine cervix might be T-BED10 > or = 100 Gy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Radiotherapy, High-Energy / methods. Salvage Therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550968.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


33. Kobayashi N, Higurashi T, Iida H, Mawatari H, Endo H, Nozaki Y, Tomimoto A, Yoneda K, Akiyama T, Fujita K, Takahashi H, Yoneda M, Inamori M, Abe Y, Kirikoshi H, Kubota K, Saito S, Ueno N, Nakajima A, Yamanaka S, Inayama Y: Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM). J Hepatobiliary Pancreat Surg; 2008;15(5):531-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM).
  • We report a rare case of adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM) in which parathyroid hormone-related protein (PTH-rP) was identified as the causative factor of hypercalcemia.
  • Autopsy demonstrated that the neoplasm in the pancreas showed an abrupt histological transition from adenocarcinoma to squamous cell carcinoma.
  • PTH-rP was identified in the primary pancreatic tumor cells by immunohistochemical examination and a reverse-transcription polymerase chain reaction (RTPCR) method.
  • This is a very rare report of adenosquamous cell carcinoma of the pancreas associated with HHM.
  • [MeSH-major] Carcinoma, Adenosquamous / complications. Hypercalcemia / etiology. Pancreatic Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836809.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  •  go-up   go-down


34. Okamoto T, Maruyama R, Suemitsu R, Aoki Y, Wataya H, Kojo M, Ichinose Y: Prognostic value of the histological subtype in completely resected non-small cell lung cancer. Interact Cardiovasc Thorac Surg; 2006 Aug;5(4):362-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of the histological subtype in completely resected non-small cell lung cancer.
  • Non-small cell lung cancer (NSCLC), which includes several different histological subtypes, is usually treated by the same strategy.
  • However, the biological behavior of each cell type appears to be different.
  • We retrospectively reviewed the clinical records of 1119 consecutive NSCLC patients who underwent a complete resection, in order to investigate whether a histological cell type is a powerful prognostic factor.
  • The overall 5- and 10-year survivals of the patients with adenocarcinoma (AD), squamous cell carcinoma (SQ), large cell carcinoma (LA), and adenosquamous cell carcinoma (AS) were 54.2 and 40.2%, 51.6 and 30.3%, 40.9 and 18.7%, and 35.1 and 30.1%, respectively.
  • The AD patients had a significantly better survival than the non-AD patients in Stage I (P=0.0004), whereas the SQ patients had a better survival than the non-SQ patients in Stage II (P=0.018).
  • A multivariate survival analysis indicated the AD patients to have a significantly better survival than the SQ patients in Stage IA (P=0.04), while the SQ patients had a better survival than the AD patients in Stage II (P=0.03).
  • These above observations suggest that the prognosis after complete resection is different between adenocarcinoma and squamous cell carcinoma in Stage IA and II.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17670594.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Shen K, Lang JH, Yang JX, Chen YL, Xiang Y, Hua KQ, Huang HF, Pan LY, Wu M, Feng YJ: [Analysis of 16 patients with early cervical cancer treated by laparoscopic vaginal radical trachelectomy]. Zhonghua Fu Chan Ke Za Zhi; 2006 Apr;41(4):222-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifteen patients had squamous cell carcinoma and 1 had adenosquamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Fertility. Laparoscopy / methods. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16759453.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


36. Chang D, Wang TY, Wei JC, Song JX, Jiao GG: [Surgical treatment of primary esophageal adenocarcinoma]. Zhonghua Wai Ke Za Zhi; 2007 May 15;45(10):681-3
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of primary esophageal adenocarcinoma].
  • OBJECTIVE: To summarize the surgical treatment and clinical bio-characteristics of primary esophageal adenocarcinoma (PEAC).
  • RESULTS: Forty-three cases PEAC were reported in this study, which were 0.8% out of 5638 cases pathologically confirmed esophageal carcinoma treated during this period.
  • Twelve cases (27.9%) were in the middle 1/3 of esophagus, thirty-one cases (72.1%) in the lower 1/3, which were significantly different from esophageal squamous cell carcinoma (ESCC).
  • Fourteen cases were pure esophageal adenocarcinoma (32.6%), twenty-nine cases were adenosquamous cell carcinoma and adenoacanthoma cell carcinoma (67.4%).
  • CONCLUSIONS: Compared with ESCC, PEAC, mainly located in the inferior 1/3 of esophagus, is a malignant disease with higher frequency of lymph node metastasis and poor prognosis.
  • Early diagnosis and early treatment as well as curative operation could improve prognosis.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17688820.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


37. Iwanami T, Uramoto H, Baba T, Takenaka M, Yokoyama E, Oka S, So T, Ono K, So T, Takenoyama M, Hanagiri T, Iwata T, Inoue M, Yasumoto K: [Treatment recommendations for adrenal metastasis of non-small cell lung cancer]. Kyobu Geka; 2010 Dec;63(13):1101-6; discussion 1106-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment recommendations for adrenal metastasis of non-small cell lung cancer].
  • To evaluate the optimum treatment strategy for metastatic adrenal tumors derived from non-small cell lung cancer (NSCLC), we retrospectively analyzed 17 consecutive cases (8 resection cases: 4 synchronous and 4 metachronous: 9 non-resection cases: 3 synchronous and 6 metachronous) who received surgical resection for NSCLC.
  • Of these, 9, 3, 2, 2, and 1 patient (s) were diagnosed as having adenocarcinoma, squamous cell carcinoma, pleomorphic carcinoma, large cell carcinoma, and adenosquamous cell carcinoma, respectively.
  • The mean time to progression from treatment of metachronous adrenal metastasis to disease progression was 8.9 months.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


38. Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S: Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation. Gynecol Oncol; 2009 Jul;114(1):69-74
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred thirty-nine FIGO stage IIB patients with squamous or adenosquamous cell carcinoma (median age, 51 years) who were treated with primary radical hysterectomy were examined retrospectively.
  • [MeSH-minor] Aged. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Rate. Survivors


39. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H: Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol; 2010 Dec 27;2(12):419-27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To date, ICC was largely classified into adenocarcinoma and rare variants.
  • The former is a tubular or micropapillary adenocarcinoma while the latter involves the intrahepatic large bile duct.
  • Hepatic progenitor cell or stem cell phenotypes such as neural cell adhesion molecule expression are frequently expressed in the bile ductular type.
  • Intraductal type includes papillary and tubular neoplasms of the bile duct (IPNBs and ITNBs) and a superficial spreading type.
  • IPNB and ITNB show a spectrum from a preneoplastic borderline lesion to carcinoma and may have pancreatic counterparts.
  • At invasive sites, IPNB is associated with the conventional bile duct ICC and mucinous carcinoma.
  • Rare variants of ICC include squamous/adenosquamous cell carcinoma, mucinous/signet ring cell carcinoma, clear cell type, undifferentiated type, neuroendocrine carcinoma and so on.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2008 Jun;215(2):175-83 [18393368.001]
  • [Cites] Mod Pathol. 2001 May;14(5):527-32 [11353065.001]
  • [Cites] J Clin Gastroenterol. 1994 Jun;18(4):335-42 [8071522.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1739-45 [15185318.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1333-43 [17058219.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):350-8 [16360234.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(4):288-91 [14598147.001]
  • [Cites] Hepatol Res. 2007 Oct;37 Suppl 3:S478-86 [17931207.001]
  • [Cites] Histopathology. 1980 Jul;4(4):391-400 [6253379.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):651-8 [11584359.001]
  • [Cites] World J Hepatol. 2009 Oct 31;1(1):35-42 [21160963.001]
  • [Cites] Lab Invest. 2009 Nov;89(11):1261-74 [19721413.001]
  • [Cites] Hepatol Res. 2008 Apr;38(4):325-34 [18093122.001]
  • [Cites] J Hepatol. 2006 Dec;45(6):856-67 [17030071.001]
  • [Cites] Microsc Res Tech. 1997 Sep 15;38(6):552-70 [9330346.001]
  • [Cites] Am J Pathol. 2009 Mar;174(3):829-41 [19218340.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1243-54 [16741522.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2145-9 [9610693.001]
  • [Cites] Cancer. 1977 Jan;39(1):232-46 [64293.001]
  • [Cites] Pathol Int. 2010 Jun;60(6):419-29 [20518896.001]
  • [Cites] Pathol Int. 2010 Jul;60(7):516-9 [20594273.001]
  • [Cites] Mod Pathol. 2007 Jun;20(6):701-9 [17431410.001]
  • [Cites] Curr Gastroenterol Rep. 2006 Feb;8(1):30-7 [16510032.001]
  • [Cites] Pathol Int. 2005 Apr;55(4):180-8 [15826244.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1193-203 [15316319.001]
  • [Cites] Hum Pathol. 2003 Dec;34(12):1337-44 [14691921.001]
  • [Cites] Histopathology. 2007 Sep;51(3):390-400 [17553067.001]
  • (PMID = 21191517.001).
  • [ISSN] 1948-5182
  • [Journal-full-title] World journal of hepatology
  • [ISO-abbreviation] World J Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3010511
  • [Keywords] NOTNLM ; Adenocarcinoma / Bile duct / Bile ductule / Intraductal neoplasm / Intrahepatic cholangiocarcinoma
  •  go-up   go-down


40. Lin Z, Liu M, Li Z, Kim C, Lee E, Kim I: DeltaNp63 protein expression in uterine cervical and endometrial cancers. J Cancer Res Clin Oncol; 2006 Dec;132(12):811-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: DeltaNp63 protein expression was studied in a variety of 127 cases of uterine cervical lesions (20 non-neoplastic cervices, 43 cervical intraepithelial neoplasia [CIN], 54 squamous cell carcinomas (SCCs), 40 adenocarcinomas, and 13 other histologic types) and 30 endometrioid type of endometrial adenocarcinomas by using immunohistochemistry.
  • One SCC cell line (ME-180) and one adenocarcinoma cell line (HeLa) were also included.
  • RESULTS: In uterine cervix, the expression of DeltaNp63 was increased with progression of CIN, and positive in all SCCs, transitional cell carcinomas, and adenoid basal carcinoma, but negative in all adenocarcinomas.
  • Adenosquamous cell carcinoma and mixed neuroendocrine and squamous cell carcinoma were positive in squamous component, but not in adenocarcinoma and neuroendocrine carcinoma components.
  • ME-180 cell line was positive, whereas HeLa cell line was negative.
  • Endometrioid type of endometrial adenocarcinomas showed a positive staining in glandular (26.7%) and squamous component.
  • CONCLUSIONS: Immunohistochemical staining for DeltaNp63 is a powerful marker for squamous differentiation and useful in exclusion of glandular and neuroendocrine differentiation in uterine cervical cancers, but not always in endometrial cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. DNA-Binding Proteins / biosynthesis. Endometrial Neoplasms / metabolism. Trans-Activators / biosynthesis. Tumor Suppressor Proteins / biosynthesis. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Antigens, Differentiation / biosynthesis. Cell Line, Tumor. Cervix Uteri / cytology. Cervix Uteri / metabolism. Female. HeLa Cells. Humans. Immunohistochemistry. Transcription Factors

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16804722.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


41. Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD: A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Am J Clin Oncol; 2008 Oct;31(5):413-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three patients with colon cancer, 1 patient with renal cell cancer and 1 patient with adenosquamous cell carcinoma of the ethmoid sinus had stable disease.
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Disease-Free Survival. Epirubicin / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838875.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


42. Tatematsu A, Shimizu J, Murakami Y, Horio Y, Nakamura S, Hida T, Mitsudomi T, Yatabe Y: Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res; 2008 Oct 1;14(19):6092-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor mutations in small cell lung cancer.
  • PURPOSE: The vast majority of epidermal growth factor receptor (EGFR) mutations occur in lung adenocarcinoma, and even rare cases of other subtypes with this mutation, such as adenosquamous cell carcinoma, are associated with adenocarcinoma histology.
  • According to this adenocarcinoma-specific nature of EGFR mutation, analysis of EGFR mutations with small cell lung cancers (SCLC) may provide a clue to its histogenesis.
  • Notably, in three tumors of the combined SCLC subtype, both components of adenocarcinoma and SCLC harbored an EGFR mutation, whereas gene amplification was detected only in the adenocarcinoma component.
  • CONCLUSIONS: Although EGFR mutations are rare in SCLC, a combined subtype of SCLC with adenocarcinoma in light smokers may have a chance of harboring EGFR mutations.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genes, erbB-1. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / physiology. Small Cell Lung Carcinoma / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829487.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


43. Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H, Kohno I: Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol; 2005 Mar;96(3):805-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 9 squamous cell carcinomas, 6 adenocarcinomas, 1 adenosquamous cell carcinoma, and 1 small cell carcinoma.
  • No progression of disease was observed.
  • All 5 adenocarcinoma patients in the neoadjuvant chemotherapy group responded including 1 pathological CR.
  • Further evaluation particularly targeted on cervical adenocarcinoma is warranted.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721429.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


44. Tsuchida M, Umezu H, Hashimoto T, Shinohara H, Koike T, Hosaka Y, Eimoto T, Hayashi JI: Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer; 2008 Dec;62(3):321-5
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the role of KIT expression in thymic carcinoma is not fully understood.
  • METHODS: Thymic epithelial tumors from 37 patients (17 thymic carcinomas and 20 thymomas) were examined.
  • RESULTS: KIT- and CD5-positive staining was observed only in thymic carcinoma.
  • Percentage of positive staining was 100% in squamous cell carcinoma, with no positive staining in other histologies, including atypical carcinoid.
  • Mutation analysis of the KIT gene was performed in 11 squamous cell carcinomas, 1 adenocarcinoma and 1 adenosquamous cell carcinoma.
  • CONCLUSIONS: Squamous cell carcinoma of the thymus frequently expressed KIT and CD5 proteins, whereas other tumors did not.
  • Unlike GIST, overexpression of KIT does not necessarily indicate gene mutation in thymic carcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Adenosquamous / genetics. Carcinoma, Squamous Cell / genetics. Mutation / genetics. Proto-Oncogene Proteins c-kit / genetics. Thymoma / genetics. Thymus Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486988.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


45. Togashi K, Koike T, Emura I, Usuda H: [Indication for limited surgery on small lung cancer tumors measuring 1cm or less in diameter on preoperative computed tomography and long-term results]. Kyobu Geka; 2008 Jul;61(7):519-22; discussion 522-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenocarcinoma was histologically diagnosed in 49 patients (79%).
  • Other histologic types included squamous cell carcinoma (8), large cell carcinoma (1), small cell carcinoma (1), carcinoid (2), and adenosquamous cell carcinoma (1).
  • There were 14 bronchioloalveolar carcinomas (25% of IA diseases).
  • There were 3 deaths from cancer recurrence, while there were no deaths in 14 patients with bronchioloalveolar carcinoma CONCLUSION: After limited surgery, non-invasive cancer showed good long-term results, while invasive cancer showed a recurrence rate of 2.3% to 79% even though the tumor measured 1 cm or less in diameter on preoperative CT.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616092.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


46. Ak I, Sivrikoz MC, Entok E, Vardareli E: Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography. Eur J Cardiothorac Surg; 2010 Apr;37(4):792-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
  • The objective of our study was to compare the sensibility of the 2-deoxy-2-[18F] fluoro-d-glucose positron emission tomography/computed tomography (F-18 FDG PET/CT) for the detection of bone metastasis in patients with non-small-cell lung cancer (NSCLC) whose technetium 99m methylenediphosphonate (Tc-99m MDP) bone scans were absolutely normal.
  • RESULTS: Nine patients had squamous cell carcinoma, six had adenocarcinoma, three had large cell carcinoma and one had adenosquamous cell carcinoma.
  • Tc-99m MDP bone scan that did not reveal bony abnormalities or radiotracer uptake was characteristic of benign disease (defined as absolutely normal) in these patients.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20015657.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


47. Koshimune R, Aoe M, Toyooka S, Hara F, Ouchida M, Tokumo M, Sano Y, Date H, Shimizu N: Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. BMC Cancer; 2007;7:8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
  • In this study, we investigate the anti-tumor effect of YM529 on non-small cell lung cancer (NSCLC).
  • METHODS: Direct anti-tumor effect of YM529 against 8 NSCLC cell lines (adenocarcinoma: H23, H1299, NCI-H1819, NCI-H2009, H44, A549, adenosquamous cell carcinoma: NCI-H125, squamous cell carcinoma: NCI-H157) were measured by MTS assay and calculated inhibition concentration 50 % (IC50) values.
  • RESULTS: We found that there was direct anti-tumor effect of YM529 on 8 NSCLC cell lines in a dose-dependent manner and their IC50 values were 2.1 to 7.9 microM and YM529 induced apoptosis and G1 arrest cell cycle with dose-dependent manner and YM529 caused down regulation of phospholyration of ERK1/2 in signaling pathways of NSCLC cell line (NCI-H1819).
  • CONCLUSION: Our study demonstrate that YM529 showed direct anti-tumor effect on NSCLC cell lines in vitro, which supports the possibility that third-generation BPs including YM529 can be one of therapeutic options for NSCLC.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Non-Small-Cell Lung / drug therapy. Diphosphonates / pharmacology. Imidazoles / pharmacology. Lung Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Humans

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Enzymol. 1987;152:180-3 [3657568.001]
  • [Cites] Oral Oncol. 2004 Jan;40(1):43-51 [14662414.001]
  • [Cites] J Clin Invest. 1991 Dec;88(6):2095-105 [1661297.001]
  • [Cites] Curr Opin Genet Dev. 1997 Feb;7(1):75-9 [9024640.001]
  • [Cites] Br J Haematol. 1997 Sep;98(3):665-72 [9332325.001]
  • [Cites] Scand J Rheumatol. 1998;27(1):38-41 [9506876.001]
  • [Cites] Leukemia. 1998 Feb;12(2):220-9 [9519785.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5294-7 [9850051.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Feb 16;255(2):491-4 [10049736.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4919-26 [10519405.001]
  • [Cites] Lung Cancer. 2005 Jan;47(1):31-9 [15603852.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):853-9 [15701876.001]
  • [Cites] Leuk Res. 2005 Apr;29(4):451-7 [15725480.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2713-9 [15814653.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer Lett. 2006 Jul 8;238(1):111-8 [16112430.001]
  • [Cites] Clin Exp Metastasis. 2006;23(1):19-31 [16715352.001]
  • [Cites] J Bone Miner Res. 1999 Dec;14(12):2048-56 [10620064.001]
  • [Cites] Arch Biochem Biophys. 2000 Jan 1;373(1):231-41 [10620343.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1459-68 [10780527.001]
  • [Cites] Leukemia. 2000 May;14(5):841-4 [10803515.001]
  • [Cites] J Bone Miner Res. 2000 Nov;15(11):2211-21 [11092402.001]
  • [Cites] Leuk Res. 2001 Jan;25(1):77-83 [11137564.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Feb;296(2):235-42 [11160603.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2602-8 [11289137.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1126-34 [11308265.001]
  • [Cites] Bone. 2001 Oct;29(4):336-43 [11595616.001]
  • [Cites] J Med Chem. 2002 Aug 15;45(17):3721-38 [12166945.001]
  • [Cites] J Clin Pharmacol. 2002 Nov;42(11):1228-36 [12412821.001]
  • [Cites] J Cell Physiol. 2003 Apr;195(1):139-50 [12599217.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1971-8 [12799645.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9268-72 [3057505.001]
  • (PMID = 17222343.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates; 0 / Imidazoles; 127657-42-5 / YM 529
  • [Other-IDs] NLM/ PMC1781945
  •  go-up   go-down


48. Huang C, Wang LC, Xiao JY, Ye ZX, Liu ZJ, Xu WJ, Cheng X, Wang J, Li K: [Analysis of cavitation of advanced NSCLC treated by rh-endostatin combined with NP chemotherapy]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):712-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 5 patients, there were 2 males and 3 females, with pathological types of 3 adenocarcinomas, 1 adenosquamous cell carcinoma and 1 sarcomatoid carcinoma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Endostatins / therapeutic use. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173919.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endostatins; 0 / Recombinant Proteins; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


49. Yaren A, Oztop I, Kargi A, Ulukus C, Onen A, Sanli A, Binicier O, Yilmaz U, Alakavuklar M: Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. Int J Clin Pract; 2006 Jun;60(6):675-82
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.
  • In non-small-cell lung cancer (NSCLC), stage of the disease is still the most important prognostic factor.
  • In this study, we aimed to evaluate the expressions of Bax and bcl-2 genes which are important in apoptosis and c-kit, which is a tyrosine kinase transmembrane receptor, as well as searched their response to treatment modalities and effects on survival.
  • Sixty-nine NSCLC cases' pathological samples were stained with specific Bax, bcl-2 and c-kit dyes by immunohistochemical (IHC) methods.
  • Their histological subtypes were as follows: of 69 cases, 36 (52.2%) were squamous cell carcinoma, 28 (40.6%) were adenocarcinoma, five (7.2%) were adenosquamous cell carcinoma (two patients) and large-cell carcinoma (three patients).
  • The positive immunostaining rates for Bax and bcl-2 in whole group, squamous cell carcinoma and adenocarcinoma groups were 40.6%/36.2%, 55.6/69.4% and 25.0/0.0%, respectively.
  • The positive immune staining rates for c-kit in whole group, squamous cell carcinoma and adenocarcinoma groups were 7.2, 5.6 and 7.1%, respectively.
  • We didn't find any correlation with Bax, bcl-2 and c-kit expressions and clinicopathological parameters such as age, tumour size, lymph node involvement, smoking, stage of the disease, response to radiotherapy and chemotherapy.
  • C-kit expression was also found not related with survival in whole group whereas found as a bad prognostic factor in patients with squamous cell carcinoma.
  • These findings could indicate that the expression of apoptotic pathway markers and c-kit may have a role in the prognosis of early stage NSCLC, especially with squamous cell carcinoma subtype.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Apoptosis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16805752.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


50. Güdücüoğlu H, Berktaş M, Bozkurt H, Toka Ozer T, Bulut G, Oztürk O, Ilhan M: [Evaluation of Western Blot method for the detection of antibodies to Helicobacter pylori antigens in patients with gastric carcinoma and cases with epigastric complaints]. Mikrobiyol Bul; 2010 Jan;44(1):21-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of Western Blot method for the detection of antibodies to Helicobacter pylori antigens in patients with gastric carcinoma and cases with epigastric complaints].
  • A total of 99 patients with gastric cancer (94 adenocarcinoma, 2 adenosquamous cell carcinoma, 3 non-Hodgkin lymphoma) and 150 control cases with epigastric complaints such as nausea, vomiting, diarrhea, gastroesophageal reflux and abdominal pain, were included to the study. H. pylori IgG-ELISA was positive in all study (mean age: 56.7 +/- 1.2 years, 62 male) and control (mean age: 24.2 +/- 1.3 years, 64 male) patients.
  • There was no statistically significant difference (p > 0.05) between gastric carcinoma and control groups in terms of CagA, HSP and flagellin antibodies (p > 0.05).
  • Further molecular and clinical studies are necessary to determine the factors that affect H. pylori virulence and disease prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20455395.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / VacA protein, Helicobacter pylori; 0 / cagA protein, Helicobacter pylori
  •  go-up   go-down


51. Ishii H, Furuse J, Boku N, Okusaka T, Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K, Fukuda H: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506. J Clin Oncol; 2009 May 20;27(15_suppl):e15578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506.
  • METHODS: Eligibility criteria included the following: patients (pts) with histologically or cytologically proven pancreatic adenocarcinoma or adenosquamous carcinoma, pts with UICC clinical stage III (T4N0-1 and M0), all lesions are assumed to be included in the radiation field of 15 cm square, age 20 or older, no prior treatment for LAPC, ECOG performance status of 0, 1 or 2, and adequate organ function.
  • Gem was given intravenously at a dose of 1,000 mg/m2 over 30 minutes on days 1, 8 and 15, repeated every 4 weeks until disease progression.
  • Serum CA 19-9 level was reduced by >50% in 37.5% of 40 pts with baseline CA19-9 >100U/ml.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962370.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Yasuda S, Kojima A, Maeno Y, Oki N, Miyahara Y, Sudo T, Takekida S, Yamaguchi S, Nishimura R: Poor prognosis of patients with stage Ib1 adenosquamous cell carcinoma of the uterine cervix with pelvic lymphnode metastasis. Kobe J Med Sci; 2006;52(1-2):9-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor prognosis of patients with stage Ib1 adenosquamous cell carcinoma of the uterine cervix with pelvic lymphnode metastasis.
  • From January 1990 to December 2004, the prognosis of 28 patients with stage Ib1 adenosquamous cell carcinoma (ASC) were assessed in comparison with those of matched counterparts of pure adenocarcinoma (ADC) and squamous cell carcinoma (SCC).
  • There was also no significant difference in the incidence of lymphatic or vascular space involvement (LVSI) and depth of stromal invasion between three cell types.
  • Since the tumor sizes of all ASC cases examined in this study were less than 4 cm, the prognoses were compared among stage Ib1 disease according to the classification system of the International Federation of Gynecology and Obstetrics (FIGO).
  • While all 9 patients in the low-risk group are alive without disease, 7 of the 19 patients in the high-risk group developed recurrence.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lymphatic Metastasis / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Staging. Pelvis. Prognosis. Retrospective Studies. Survival Rate


53. Jiang L, Ji N, Zhou Y, Li J, Liu X, Wang Z, Chen Q, Zeng X: CAL 27 is an oral adenosquamous carcinoma cell line. Oral Oncol; 2009 Nov;45(11):e204-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CAL 27 is an oral adenosquamous carcinoma cell line.
  • CAL 27 is one of the most frequently used cell lines in the field of oral squamous cell carcinoma (OSCC) studying.
  • Then, we performed tumor formation assay, HE staining and immunohistochemistry assay to further study the growing characteristics and histopathological diagnosis of CAL 27 xenografts.
  • The CAL 27 xenografts were then diagnosed as oral adenosquamous carcinomas.
  • Thus CAL 27 appears to be an oral adenosquamous carcinoma cell line.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Cell Line, Tumor / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Carcinoma / pathology. Carcinoma, Squamous Cell. Head and Neck Neoplasms / pathology. Humans. Neoplasms, Squamous Cell / pathology. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19631575.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Carcinoma, squamous cell of head and neck
  •  go-up   go-down


54. Terada T: Adenosquamous carcinoma of the ovary arising from endometriosis: two case reports. Cases J; 2009;2:6661

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the ovary arising from endometriosis: two case reports.
  • The author reports two cases of adenosquamous carcinoma arising from endometriosis of ovaries.
  • Both patients underwent hysterectomy and bilateral salpingo-oophorectomy for ovarian carcinomas.
  • Histologically, the cystic areas consisted of endometrial glandular epithelium.
  • Both mural tumors were composed of grade I endometroid adenocarcinoma and squamous cell carcinoma.
  • A differentiation of endometrioid adenocarcinoma from the endometriosis were present in a few areas.
  • Likewise, a differentiation of squamous cell carcinoma from the endometriosis were recognized in several areas.
  • The pathologic diagnosis was adenosquamous carcinoma arising from endometriosis of the ovary in both cases, rather than endometrioid adenocarcinoma with malignant squamous differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Jul;42(1):326-9 [208753.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:11-7 [11093056.001]
  • [Cites] Clin Obstet Gynecol. 1966 Jun;9(2):384-411 [5330412.001]
  • [Cites] Gynecol Oncol. 1988 May;30(1):143-8 [3366390.001]
  • (PMID = 20184682.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827079
  •  go-up   go-down


55. Lada PE, Taborda B, Sánchez M, Tommasino J, Rosso FF, Gramática L, Alecha Gil J, Echenique Elizondo M: [Adenosquamous and squamous carcinoma of the gallbladder]. Cir Esp; 2007 Apr;81(4):202-6
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenosquamous and squamous carcinoma of the gallbladder].
  • [Transliterated title] Carcinoma adenoescamoso y epidermoide de la vesícula biliar.
  • INTRODUCTION: Squamous and adenosquamous carcinomas of the gallbladder have poor prognosis.
  • MATERIAL AND METHOD: We performed a retrospective observational study of five patients with squamous or adenosquamous carcinoma of the gallbladder.
  • None of the patients had jaundice and all had gallstone disease.
  • Pathologic analysis revealed epidermoid carcinoma in two patients and adenosquamous carcinoma in three patients.
  • CONCLUSIONS: In both histological types of gallbladder carcinoma, treatment depends on the grade of local and regional invasion and tumor spread at diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Gallbladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403356.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


56. Dong Y, Wang J, Ma H, Zhou H, Lu G, Zhou X: Primary adenosquamous carcinoma of the colon: report of five cases. Surg Today; 2009;39(7):619-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenosquamous carcinoma of the colon: report of five cases.
  • Primary adenosquamous cell carcinomas (Ad-SCCs) of the colon and rectum are rare malignancies with a poor prognosis, in comparison to adenocarcinoma alone.
  • Different roles of human papilloma virus (HPV) in its pathogenesis have been reported and the role of P16 in Ad-SCCs has not been explored.
  • This report presents five cases of Ad-SCC of the colon to explore the clinicopathological features and the roles of P16, HPV 6/11, and 16/18.
  • There was no confirmed evidence to support the relationship between the infection of HPV 6/11, 16/18, and pathogenesis of Ad-SCC of the colon.
  • P16 overexpression was not related to HPV carcinogenesis and there might be another mechanism of P16 upregulation in Ad-SCC of the colon.
  • [MeSH-major] Alphapapillomavirus / isolation & purification. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / virology. Colonic Neoplasms / pathology. Colonic Neoplasms / virology. Papillomavirus Infections / virology

  • MedlinePlus Health Information. consumer health - HPV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562453.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P16 protein, human
  •  go-up   go-down


57. Kim YS, Heo WS, Chae KH, Gang YS, Jung JH, Kim SH, Seong JK, Lee BS, Jeong HY, Song KS, Shin KS, Cho JS, Noh SM: [Clinicopathological features and differences of p53 and Ki-67 expression in adenosquamous and squamous cell carcinomas of the stomach]. Korean J Gastroenterol; 2006 Jun;47(6):425-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological features and differences of p53 and Ki-67 expression in adenosquamous and squamous cell carcinomas of the stomach].
  • BACKGROUND/AIMS: This study reviews the clinicopathological features, prognosis, and differences in the expression of p53 and Ki-67 immunochemical staining in squamous cell and adenosquamous carcinoma of the stomach.
  • METHODS: From January 1995 to June 2005, 2,282 cases of gastric carcinoma were resected surgically in our hospital and 191 additional cases were resected by endoscopic mucosal resection.
  • RESULTS: The study consists of eight cases (0.032%) of primary squamous cell carcinoma (one case) and adenosquamous carcinoma (seven cases) without early gastric cancer.
  • The clinical presentation and physical findings did not differ from those of adenocarcinoma.
  • At the initial diagnosis, six (75%) were stage IV based on TNM tumor staging.
  • CONCLUSIONS: Adenosquamous and squamous cell carcinoma of the stomach are very rare.
  • They tend to be at advanced stages on initial diagnosis, and progress rapidly.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / pathology. Ki-67 Antigen / analysis. Stomach Neoplasms / pathology. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809949.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


58. Nadeau DP, Shick PC, Lindsay R: Adenosquamous carcinoma of the lateral oropharyngeal wall. Ear Nose Throat J; 2010 Nov;89(11):E18-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the lateral oropharyngeal wall.
  • Adenosquamous carcinoma of the head and neck is a rare and aggressive tumor, with fewer than 100 cases reported in the world literature to date.
  • We report a case of adenosquamous carcinoma of the oral pharynx arising as a second primary malignancy in a patient being treated for primary gastric MALT (mucosa-associated lymphoid tissue) lymphoma.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Neoplasms, Second Primary / pathology. Oropharyngeal Neoplasms / pathology
  • [MeSH-minor] Humans. Lymphoma, B-Cell, Marginal Zone / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086267.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


59. He YT, Wang XJ, Gong J, Chen N, Zhou Q: Primary adenosquamous carcinoma of the jejunum. Pathol Int; 2005 Sep;55(9):590-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenosquamous carcinoma of the jejunum.
  • Adenosquamous carcinomas of the small intestine are extremely rare, with only three documented jejunal and three ileal cases being reported in the English-language medical literature.
  • Presented herein is a case of primary jejunal adenosquamous carcinoma in an 80-year-old woman.
  • The jejunal carcinoma consisted predominantly of a squamous component throughout the tumor but peritoneal nodules carrying metastases from the adenocarcinoma element were noted, making it the first case of jejunal adenosquamous carcinoma with metastases from the adenocarcinoma component.
  • The finding that metastases could arise from the minor component of a jejunal adenosquamous carcinoma indicates that an accurate diagnosis must be based upon thorough examination of both the primary and the metastases, not just mesenteric nodule biopsy alone.
  • Histological foci of closely intermingled squamous and glandular components with apparent morphological transition were noted, indicating the pathogenetic possibility that the squamous component might arise by transformation from the glandular element.
  • The squamous component was strongly positive with immunostaining for p63 (nuclear staining) and for cytokeratin 10/13 (cytoplasmic staining), while the adenocarcinoma element was negative.
  • The immunohistochemical results suggest that p63 and cytokeratin 10/13 might be useful in identifying squamous differentiation in jejunal carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / secondary. Jejunal Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Nucleus / chemistry. Cell Nucleus / pathology. Cytoplasm / chemistry. Cytoplasm / pathology. DNA-Binding Proteins. Fatal Outcome. Female. Genes, Tumor Suppressor. Humans. Immunoenzyme Techniques. Keratins / analysis. Phosphoproteins / analysis. Trans-Activators / analysis. Transcription Factors. Tumor Suppressor Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143036.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


60. Egilmez T, Bal N, Guvel S, Kilinc F, Ozkardes H: Adenosquamous carcinoma of the prostate. Int J Urol; 2005 Mar;12(3):319-21
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the prostate.
  • Adenosquamous carcinoma of the prostate is an unusual histological variant of prostate cancer.
  • The stimulus for the development of the squamous metaplastic cells had been thought to be related to hormone and/or radiation therapy.
  • This report presents a case of adenosquamous carcinoma of the prostate with abscence of previous hormone or radiation therapy.
  • The case showed negative prostate-specific antigen and high molecular weight cytokeratin staining of the adenocarcinoma component, and negative prostate-specific antigen and positive high molecular weight cytokeratin staining of the squamous cell carcinoma component.
  • The adenocarcinoma component stained intraluminally with periodic acid schiff.
  • The staining features and the distinct localizations of the components with intermingling, but no transition, are against the collision-type tumor theory and support the theory that the adenocarcinoma and squamous components arise de novo from pluripotent stem cells.
  • The patient had a rapid downhill clinical course and died 3 weeks after the diagnosis was made.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Prostatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15828965.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


61. Uchikado Y, Natsugoe S, Okumura H, Matsumoto M, Setoyama T, Takigawa J, Haraguchi Y, Ishigami S, Aikou T: [A case of successful treatment by low-dose 5-fluorouracil and cisplatin for liver metastases of esophageal adenosquamous carcinoma]. Gan To Kagaku Ryoho; 2006 Jan;33(1):83-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successful treatment by low-dose 5-fluorouracil and cisplatin for liver metastases of esophageal adenosquamous carcinoma].
  • Adenosquamous carcinoma of the esophagus is an uncommon type of esophageal tumor.
  • In the present case, a 54-year-old man without symptoms was diagnosed with esophageal squamous cell carcinoma, based on endoscopic examination of a biopsy specimen.
  • The histological diagnosis was adenosquamous carcinoma with no lymph node metastasis.
  • Based on the present findings, we recommend low-dose 5-fluorouracil/cisplatin therapy for liver metastasis from esophageal adenosquamous carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Esophageal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410703.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


62. Mingoli A, Brachini G, Petroni R, Antoniozzi A, Cavaliere F, Simonelli L, Chirletti P, Modini C: Squamous and adenosquamous cell carcinomas of the gallbladder. J Exp Clin Cancer Res; 2005 Mar;24(1):143-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous and adenosquamous cell carcinomas of the gallbladder.
  • Squamous and adenosquamous cell carcinomas (ASC and SCC) are rare subtypes of gallbladder cancer, traditionally considered more aggressive and with a poorer prognosis than adenocarcinoma.
  • We report about two patients affected by an advanced squamous cell carcinoma of the gallbladder.
  • In conclusion, an aggressive and radical surgical treatment of advanced squamous and adenosquamous cell gallbladder carcinomas seems to be indicated for their low proclivity to distant spreading.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / pathology. Gallbladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943044.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 50
  •  go-up   go-down


63. Stelow EB, Mills SE: Squamous cell carcinoma variants of the upper aerodigestive tract. Am J Clin Pathol; 2005 Dec;124 Suppl:S96-109
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma variants of the upper aerodigestive tract.
  • Squamous cell carcinoma (SCC) is by far the most common malignancy of the upper aerodigestive tract.
  • Certain variants, however, can histologically mimic benign and other malignant diseases.
  • In such cases, correct diagnosis is important for prognostic and therapeutic reasons.
  • This article discusses the clinicopathologic features of the upper aerodigestive tract variants of SCC, including verrucous carcinoma, papillary squamous cell carcinoma, basaloid squamous cell carcinoma, spindle cell carcinoma, adenosquamous carcinoma, adenoid squamous cell carcinoma, and undifferentiated carcinoma.
  • It also discusses the differential diagnoses that must be considered and the use of ancillary testing, especially immunohistochemical analysis, for determining the correct diagnosis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Digestive System Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Adenosquamous / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Papillary / pathology. Humans

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468420.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 109
  •  go-up   go-down


64. Imura J, Tomita S, Ono Y, Inaba F, Yamazaki T, Fukasawa I, Inaba N, Fujimori T: Endometrial adenosquamous carcinoma with osteoclast-like giant cells: immunohistochemistry and histogenesis. APMIS; 2005 Feb;113(2):140-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenosquamous carcinoma with osteoclast-like giant cells: immunohistochemistry and histogenesis.
  • We herein describe a case of adenosquamous carcinoma that developed in the endometrium together with non-neoplastic OGCs.
  • Histologically, the tumor was found to be an adenosquamous carcinoma containing a large number of OGCs and mononuclear cells (MNCs) that had infiltrated into the stroma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Endometrial Neoplasms / pathology. Giant Cells / pathology. Osteoclasts / pathology
  • [MeSH-minor] Aged. Cell Lineage. Female. Humans. Leukocytes, Mononuclear / metabolism. Leukocytes, Mononuclear / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15723689.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


65. Amălinei C, Balan R, Stolnicu S, Rădulescu D, Boeru C, Cotuţiu C: Adenosquamous cervical carcinoma morphological characteristics. Rev Med Chir Soc Med Nat Iasi; 2005 Apr-Jun;109(2):343-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous cervical carcinoma morphological characteristics.
  • Adenosquamous carcinomas range between 5-25% of cervical cancers and are composed by an admixture of malignant squamous and glandular elements.
  • Differential diagnosis with endometrioid adenocarcinoma of the cervix with squamous metaplasia was made.
  • Four cases (26.66%) were subtyped as clear cell adenosquamous carcinomas and 2 cases (13.33%) were subtyped as glassy cell carcinomas, exhibiting finely granular ground glass type cytoplasm.
  • 93.33% of cases exhibited a poorly differentiated squamous component and 66.66% of cases exhibited a well differentiated glandular component.
  • Squamous intraepithelial lesions in overlying epithelium was observed in 4 cases (26.66%).
  • One case, diagnosed as glassy cell subtype, presented regional lymph node metastases.
  • Our study concluded the occurrence of adenosquamous cervical carcinomas at a similar age with squamous cervical carcinomas in the investigated group of patients.
  • As adenosquamous cervical carcinomas are considered expressions of a biphasic differentiation of a single pluripotential sub-columnar reserve cell, a similar degree of differentiation of the two components would be expected.
  • Although, we registered a degree of variability in grading of the two components, with a tendency of squamous component toward poorly differentiated aspect and a slightly dominant aspect of well differentiated glandular pattern.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607797.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


66. Geyer FC, Lambros MB, Natrajan R, Mehta R, Mackay A, Savage K, Parry S, Ashworth A, Badve S, Reis-Filho JS: Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. Mod Pathol; 2010 Jul;23(7):951-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast.
  • Breast adenosquamous carcinomas are rare tumours characterized by well-developed gland formation intimately admixed with solid nests of squamous cells immersed in a highly cellular spindle cell stroma.
  • Here we studied five cases of adenosquamous carcinomas to determine their genetic profiles and to investigate whether the spindle cell component of these cancers could at least in part stem from the glandular/epithelial components.
  • Five adenosquamous carcinomas of the breast were subjected to (1) immunohistochemical analysis, (2) microdissection and genetic analysis with a high-resolution microarray comparative genomic hybridization platform, and (3) chromogenic in situ hybridization.
  • In conclusion, breast adenosquamous carcinomas are triple-negative cancers that express 'basal' keratins.
  • Some of the spindle cells in adenosquamous carcinomas are derived from the epithelial component, suggesting that adenosquamous carcinomas may also be part of the group of metaplastic breast carcinomas with spindle cell metaplastic elements.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20453835.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


67. Sheahan P, Toner M, Timon CV: Clinicopathological features of head and neck adenosquamous carcinoma. ORL J Otorhinolaryngol Relat Spec; 2005;67(1):10-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of head and neck adenosquamous carcinoma.
  • Adenosquamous carcinoma is a rare tumour which is characterized pathologically by the simultaneous presence of distinct areas of squamous cell carcinoma and adenocarcinoma.
  • The origin of adenosquamous carcinoma is controversial; however, it is generally considered to be aggressive and associated with a dismal prognosis.
  • In the present study, the medical and pathological records of 4 patients with head and neck adenosquamous carcinoma are reviewed.
  • In 1 patient, the tumour arose from an area of carcinoma in situ of surface epithelium.
  • One patient died of postoperative complications, 1 suffered from local recurrence and developed distant metastases and 2 were alive with no evidence of disease over 30 months later.
  • Adenosquamous carcinoma is an aggressive tumour; however, with appropriate treatment, some patients may remain well beyond 2 years.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Head and Neck Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15637416.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


68. Yu JQ, Yang ZG, Austin JH, Guo YK, Zhang SF: Adenosquamous carcinoma of the lung: CT-pathological correlation. Clin Radiol; 2005 Mar;60(3):364-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the lung: CT-pathological correlation.
  • AIM: To correlate CT morphological features and histopathological findings of adenosquamous carcinoma of the lung.
  • MATERIALS AND METHODS: In all, 29 patients underwent contrast-enhanced CT of an adenosquamous carcinoma of the lung, followed by resection of the cancer.
  • These CT features corresponded mainly to solid tumour growth, which was composed of both squamous cell carcinomatous and adenocarcinomatous tissue.
  • CONCLUSION: Adenosquamous carcinoma of the lung is shown to be characteristically a solid, lobulated nodule or mass, more commonly peripheral than central.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15710140.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Kang SM, Kang HJ, Shin JH, Kim H, Shin DH, Kim SK, Kim JH, Chung KY, Kim SK, Chang J: Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer; 2007 Feb 1;109(3):581-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung.
  • BACKGROUND: Adenosquamous carcinoma of the lung is composed of adenocarcinomatous and squamous cell carcinomatous components.
  • The epidermal growth factor receptor (EGFR) mutations occur mostly in adenocarcinomas and rarely in squamous cell carcinoma of lung.
  • Attempts to investigate the EGFR mutation status in each component of adenosquamous carcinoma and to characterize the patients according to mutation status may help to understand the histogenesis of adenosquamous carcinoma.
  • METHODS: The mutation status of EGFR kinase domain from exon 18 to 21 was investigated in 25 Korean patients with adenosquamous carcinoma by polymerase chain reaction-single strand conformation polymorphism using the tissues of each component from the adenosquamous carcinoma tumor.
  • Identical EGFR mutations in both components of adenosquamous carcinoma were confirmed by nucleotide sequencing.
  • CONCLUSIONS: The frequency of EGFR mutation and clinicopathologic characteristics of the EGFR mutants in adenosquamous carcinoma are similar to those of Asian patients with adenocarcinomas.
  • Identical EGFR mutations in both components suggest the possibility of monoclonality in the histogenesis of adenosquamous carcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Adenosquamous / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Lung Neoplasms / genetics. Mutation / genetics. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17186532.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


70. Damadoğlu E, Aybatli A, Yalçinsoy M, Tahaoğlu C, Atasalihi A, Akkaya E, Yilmaz A: [Adenosquamous carcinoma of the lung (an analysis of 13 cases)]. Tuberk Toraks; 2005;53(2):161-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenosquamous carcinoma of the lung (an analysis of 13 cases)].
  • Adenosquamous carcinoma of the lung is a rare disease.
  • In this study, we retrospectively evaluated 13 patients with adenosquamous carcinoma of the lung diagnosed at our center between January 2001 and May 2004.
  • Preoperative pathological diagnosis was squamous cell carcinoma in eight patients, non-small cell lung carcinoma in four patients and adenocarcinoma in one patient.
  • Five patients died of disease within 3 and 21 months.
  • [MeSH-major] Carcinoma, Adenosquamous / epidemiology. Lung Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100653.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


71. dos Reis R, Frumovitz M, Milam MR, Capp E, Sun CC, Coleman RL, Ramirez PT: Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis. Gynecol Oncol; 2007 Dec;107(3):458-63
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis.
  • OBJECTIVE: To evaluate whether histology (adenocarcinoma versus adenosquamous carcinoma) is an independent prognostic indicator in patients with stage IB1 cervical cancer after radical hysterectomy.
  • METHODS: All patients with adenocarcinoma or adenosquamous carcinoma who underwent radical hysterectomy between October 1990 and December 2006 at The University of Texas M. D.
  • Clinico-pathological data collected included age, disease stage, tumor grade, lymph node status, parametrial involvement, depth of invasion, evidence of lymph-vascular space invasion (LVSI), and adjuvant therapy.
  • Patients were categorized as having "low-risk" or "high-risk" disease depending on the final pathologic findings.
  • RESULTS: We identified 126 patients with stage IB1 adenosquamous (n=29) or adenocarcinoma (n=97) cervical cancer.
  • The median age was 40.3 years for patients with adenocarcinoma and 35.2 years for patients with adenosquamous carcinoma (P=0.88).
  • Grade III histology and LVSI were more common in patients with adenosquamous tumors than in patients with adenocarcinoma (85% versus 16%; P<0.01 and 56.5% versus 32.8; P=0.04).
  • There was no difference in recurrence rates between the two histologic groups, but the time to recurrence was shorter for patients with adenosquamous carcinoma (7.9 months versus 15 months; P=0.01).
  • There was no difference between cell types with regards to recurrence and recurrence-free survival rates in the low- and high-risk groups.
  • CONCLUSION: We found no evidence that histologic subtype affects outcome; however, the median time to recurrence was shorter in patients with adenosquamous carcinoma.
  • Our study suggests that in patients with stage IB1 adenosquamous carcinoma or adenocarcinoma, the presence of high-risk features is more important than histologic subtype.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17854872.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


72. Sato T, Ito J, Shibuya H, Asano K, Watari T: Pulmonary adenosquamous carcinoma in a dog. J Vet Med A Physiol Pathol Clin Med; 2005 Dec;52(10):510-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary adenosquamous carcinoma in a dog.
  • A mass that developed in the lung of a 10-year-old mixed-breed dog was pathologically examined.
  • Histopathological examination showed papillary and tubular growth of glandular epithelium-like cells in some areas and growth of squamous cells arranged in nests in other areas, showing coexistence of adenocarcinoma and squamous cell carcinoma in a lung tumour.
  • Electron microscopically, the neoplastic cells of the adenocarcinoma component had features of glandular cells, with microvilli, numerous free ribosomes, large round secretory granules and intercellular desmosomes.
  • Non-keratinized squamous cells had tonofilaments and intercellular desmosomes.
  • These findings led to the diagnosis of primary adenosquamous carcinoma, which demonstrates phenotypic profiles characteristic of both epidermal keratinocytes and glandular epithelium.
  • [MeSH-major] Carcinoma, Adenosquamous / veterinary. Dog Diseases / pathology. Lung Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300659.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


73. Zhang DK, Su XD, Lin P, Long H, Fu JH, Zhang LJ, Ma GW, Rong TH: [Clinical analysis of 22 cases of esophageal adenosquamous carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Apr;31(4):302-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 22 cases of esophageal adenosquamous carcinoma].
  • OBJECTIVE: This study was to review the clinical features, diagnosis, treatment, and prognosis of esophageal adenosquamous carcinoma (ASC).
  • Esophageal ASC showed similar clinical symptoms, radiological and endoscopic features to esophageal squamous cell carcinoma (ESCC).
  • CONCLUSION: Esophageal adenosquamous carcinoma is a rare esophageal disease and prone to be misdiagnosed as esophageal squamous cell carcinoma.
  • The prognosis of esophageal adenosquamous carcinoma has not yet been well established.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Diagnostic Errors. Esophageal Neoplasms / diagnosis. Esophagectomy / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615289.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Suzuki S, Hanata K, Nanjo H, Ishikawa K: Adenosquamous carcinoma of maxillary sinus: case showing complete response to S-1. J Laryngol Otol; 2009 Nov;123(11):1271-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of maxillary sinus: case showing complete response to S-1.
  • BACKGROUND: Adenosquamous carcinoma is a very rare tumour which is characterised pathologically by the simultaneous presence of distinct areas of adenocarcinoma and squamous cell carcinoma.
  • Generally, adenosquamous carcinoma has an aggressive clinical course and is associated with a poor prognosis.
  • Chemotherapy is rarely used in treating adenosquamous carcinoma, and it has been difficult to establish treatment guidelines due to the paucity of cases.
  • CASE: We report a case of adenosquamous carcinoma which arose in the maxillary sinus of a 77-year-old man.
  • CONCLUSION: This report presents the aggressive character of adenosquamous carcinoma and the possible role of S-1 in the treatment of this uncommon neoplasm.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Adenosquamous / drug therapy. Maxillary Sinus Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19152726.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


75. Terada T: Adenosquamous carcinoma in a congenital choledochal cyst associated with pancreatico-biliary maljunction. Pathol Int; 2009 Jul;59(7):482-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma in a congenital choledochal cyst associated with pancreatico-biliary maljunction.
  • Congenital choledochal cyst is occasionally complicated by carcinomatous transformation, mostly adenocarcinoma.
  • Adenosquamous carcinoma arising in a congenital choledochal cyst is very rare.
  • The author herein reports an adenosquamous carcinoma arising in congenital choledochal cyst associated with pancreatico-biliary maljunction.
  • Because clinical cytology of bile indicated malignant cells, pancreatico-duodenectomy, cholecystectomy, and resection of the choledochal cyst were performed.
  • Histologically, the lesion was composed of a squamous cell carcinoma element and an adenocarcinoma element; a gradual transition was recognized between the two.
  • The squamous cell carcinoma element contained microcytic cells with mucins.
  • On immunohistochemistry the adenocarcinoma element and microcytic cells were positive for CEA, but the squamous cell carcinoma element was negative for CEA.
  • Ki-67 labeling was 53% in the adenocarcinoma element and 48% in the squamous cell carcinoma element. p53 protein was negative in both elements.
  • The present case is the second case of adenosquamous carcinoma arising in congenital choledochal cyst in the English-language literature.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Carcinoma, Adenosquamous / pathology. Choledochal Cyst / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563412.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


76. Longatto-Filho A, Pinheiro C, Martinho O, Moreira MA, Ribeiro LF, Queiroz GS, Schmitt FC, Baltazar F, Reis RM: Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. BMC Cancer; 2009 Jun 29;9:212
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.
  • BACKGROUND: Adenosquamous carcinoma of the uterine cervix is an infrequent but aggressive subtype of cervical cancer.
  • The objective of this study was to investigate EGFR, PDGFRA and VEGFR2 RTKs overexpression and activating gene mutations in a cohort of 30 adenosquamous carcinomas of the uterine cervix.
  • All PDGFRA immunohistochemical reactions were positive and consistently observed in the stromal component, staining fibroblasts and endothelial cells, as well as in the cytoplasm of malignant cells.
  • We also observed the presence of base substitutions in intron 14 (IVS14+3G>A and IVS14+49G>A) in two different cases, and in intron 18 (IVS18-50insA) in 4 cases.
  • CONCLUSION: This is the most extensive analysis of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinomas.
  • Despite the absence of EGFR and PDGFRA activating mutations, the presence of overexpression of these three important therapeutic targets in a subset of cases may be important in predicting the sensitivity of adenosquamous carcinoma to specific anti-RTKs drugs.
  • [MeSH-major] Carcinoma / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Receptor, Epidermal Growth Factor / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. Uterine Cervical Neoplasms / genetics. Vascular Endothelial Growth Factor Receptor-2 / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e19 [18232728.001]
  • [Cites] Curr Opin Investig Drugs. 2008 Dec;9(12):1324-35 [19037839.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] Cancer. 2003 May 1;97(9):2196-202 [12712471.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):414-9 [12798704.001]
  • [Cites] Histopathology. 2003 Jul;43(1):33-9 [12823710.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2985-91 [12912946.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):346-53 [14599865.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):558-62 [14675676.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1366-74 [14977838.001]
  • [Cites] J Pathol. 2004 Mar;202(3):313-20 [14991896.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Biochemistry. 1987 Mar 10;26(5):1443-51 [3494473.001]
  • [Cites] J Clin Pathol. 1993 Feb;46(2):149-53 [8459036.001]
  • [Cites] J Virol. 1993 Aug;67(8):4521-32 [8392596.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):433-40 [8697388.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):577-86 [10100709.001]
  • [Cites] Cell Mol Life Sci. 2004 Dec;61(23):2924-31 [15583854.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):207-10 [15791479.001]
  • [Cites] Oncogene. 2005 Apr 7;24(15):2585-8 [15735736.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R788-95 [16168125.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Mod Pathol. 2006 May;19(5):701-7 [16557278.001]
  • [Cites] Clin Transl Oncol. 2006 Feb;8(2):77-82 [16632420.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):91-8 [16450401.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):407-20 [16890796.001]
  • [Cites] J Pathol. 2006 Aug;209(4):445-53 [16739104.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):235-41 [17581404.001]
  • [Cites] Drugs. 2007;67(14):2045-75 [17883287.001]
  • [Cites] Oncol Rep. 2007 Nov;18(5):1201-6 [17914573.001]
  • [Cites] Curr Med Chem. 2007;14(23):2495-516 [17979703.001]
  • [Cites] Oncol Rep. 2008 Jan;19(1):65-71 [18097577.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):42-6 [17980406.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):182-90 [18028988.001]
  • [Cites] J Clin Pathol. 2008 Feb;61(2):203-8 [17827398.001]
  • [Cites] PLoS One. 2008;3(2):e1652 [18286204.001]
  • [Cites] Gynakol Geburtshilfliche Rundsch. 2008;48(2):94-100 [18431049.001]
  • [Cites] J Gastroenterol. 2008;43(7):499-508 [18648736.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jul-Aug;18(4):749-54 [17949425.001]
  • [Cites] BMC Cancer. 2008;8:232 [18700025.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S72-6 [18544460.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88 [18985183.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):350-5 [18708242.001]
  • [Cites] Drugs. 2000;60 Suppl 1:15-23; discussion 41-2 [11129168.001]
  • (PMID = 19563658.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC2711112
  •  go-up   go-down


77. Fu JM, McCalmont T, Yu SS: Adenosquamous carcinoma of the skin: a case series. Arch Dermatol; 2009 Oct;145(10):1152-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the skin: a case series.
  • BACKGROUND: Adenosquamous carcinoma is an uncommon cutaneous malignant neoplasm with mixed glandular and squamous differentiation and a propensity for aggressive clinical behavior.
  • OBSERVATIONS: Of 27 patients diagnosed as having adenosquamous carcinoma, 19 were men and 5 were immunosuppressed.
  • Squamous and glandular differentiation was characteristic.
  • CONCLUSIONS: Adenosquamous carcinoma is best considered as a locally aggressive high-risk subtype of cutaneous squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19841403.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Ogura K, Ishi K, Matsumoto T, Kina K, Nojima M, Suda K: Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas. Pathol Int; 2006 Jun;56(6):301-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas.
  • Many studies have suggested that human papillomavirus (HPV) infection plays an important role in the carcinogenesis of the cervical adenocarcinoma.
  • However, the prevalence of HPV infection in cervical adenocarcinoma and adenosquamous carcinoma varies among the studies.
  • Cervical adenocarcinoma (24 cases) and adenosquamous carcinoma (16 cases), including the underlying non-neoplastic epithelium were examined for HPV-DNA using in situ polymerase chain reaction (PCR), which enabled visualization of the localization on a glass slide.
  • In adenocarcinoma, HPV-DNA was found in 13 cases (54%) and in eight cases in underlying non-neoplastic epithelium, resulting in a total of 21 positive cases (88%).
  • In adenosquamous carcinoma, HPV-DNA was detected in 12 cases (75%) and and the HPV-DNA localization of each component was pure adenocarcinoma, 28.6%; mixed, 54.5%; and pure squamous cell carcinoma, 83.3%.
  • In the underlying non-neoplastic epithelium, HPV-DNA was found more frequently in the squamous epithelium (73.3%) than the cervical glands (6.3%).
  • In conclusion, HPV-DNA was detected in 54% of adenocarcinoma, and the rate was elevated by HPV localization in the underlying non-neoplastic epithelium.
  • HPV infection in the underlying squamous epithelium might be related to the carcinogenesis, even in cervical adenocarcinoma.
  • HPV-DNA localization was different in each component of adenosquamous carcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16704493.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / DNA Probes, HPV; 0 / DNA, Viral
  •  go-up   go-down


79. Hong SM, Kim MJ, Jang KT, Yoon GS, Cho H, Frierson HF, Yu E: Adenosquamous carcinoma of extrahepatic bile duct: clinicopathologic study of 12 cases. Int J Clin Exp Pathol; 2008;1(2):147-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of extrahepatic bile duct: clinicopathologic study of 12 cases.
  • Adenosquamous carcinoma is a rare histologic subtype of extrahepatic bile duct (EBD) carcinoma and limited information is available on its clinicopathologic characteristics.
  • Twelve cases of adenosquamous carcinoma were collected from 3 institutions and their clinicopathologic characteristics were examined and compared with those of 176 EBD adenocarcinomas.
  • The adenocarcinoma component was more often seen at the surface of the tumor (7 of 12 cases, 58%), while the squamous carcinoma component was slightly more frequent at the advanced edge (7 of 12 cases, 58%).
  • Immunohistochemistry, available in 10 cases, revealed that S100A2 was positive in the squamous carcinoma component in all 10 cases (100%), while it was present in the adenocarcinoma component in only 2 of 10 cases (20%, chi-square test, p=0.001).
  • Patients with adenosquamous carcinomas had worse survival (median survival, 11 months) than those with adenocarcinoma (median survival, 32 months; log-rank test, p=0.003).
  • Patients with predominant squamous cell carcinoma component at the leading edge had worse survival than those without it.
  • In conclusion, patients with adenosquamous carcinoma demonstrated worse survival than those with pure adenocarcinoma.
  • S100A2 immunohistochemical staining may be helpful in detecting the squamous component.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):199-206 [17255764.001]
  • [Cites] J Gastroenterol. 2000;35(6):465-71 [10864356.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):802-10 [15959914.001]
  • [Cites] J Gastroenterol. 2005 Feb;40(2):192-9 [15770404.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):258-63 [10211505.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2309-16 [9815629.001]
  • [Cites] Diagn Cytopathol. 1996 Nov;15(4):322-4 [8982588.001]
  • [Cites] Ryoikibetsu Shokogun Shirizu. 1996;(9):61-3 [8705560.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1994 Feb;32(2):161-7 [8164404.001]
  • [Cites] J Gastroenterol Hepatol. 1993 Nov-Dec;8(6):607-12 [8280849.001]
  • [Cites] J Surg Oncol. 1986 Oct;33(2):140-2 [3531727.001]
  • [Cites] Ann Thorac Surg. 1987 Nov;44(5):462-6 [3675050.001]
  • [Cites] J Surg Oncol. 1980;15(1):29-35 [7421268.001]
  • [Cites] South Med J. 1978 Feb;71(2):216-9 [622635.001]
  • [Cites] Methods Mol Biol. 2005;289:209-22 [15502186.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1515-24 [15467767.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22 [15336958.001]
  • [Cites] Biochem Cell Biol. 2004 Aug;82(4):508-15 [15284904.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):300-4 [15278069.001]
  • [Cites] Tumour Biol. 2004 Jan-Apr;25(1-2):31-40 [15192310.001]
  • [Cites] Chir Ital. 2004 Mar-Apr;56(2):289-95 [15152526.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):558-62 [14675676.001]
  • [Cites] Cancer. 2003 May 1;97(9):2196-202 [12712471.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6823-6 [12460893.001]
  • [Cites] Histol Histopathol. 2002 Jan;17(1):123-30 [11813862.001]
  • [Cites] Pathologica. 2000 Oct;92(5):323-6 [11198466.001]
  • [Cites] Int J Mol Med. 2000 Nov;6(5):539-42 [11029520.001]
  • [Cites] Neoplasia. 2006 Oct;8(10):843-50 [17032501.001]
  • (PMID = 18784802.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480552
  • [Keywords] NOTNLM ; Adenosquamous carcinoma / S100A2 / cholangiocarcinoma / extrahepatic bile duct / prognosis
  •  go-up   go-down


80. Skafida E, Grammatoglou X, Glava C, Zissis D, Paschalidis N, Katsamagkou E, Firfiris N, Vasilakaki T: Adenosquamous carcinoma of the pancreas: a case report. Cases J; 2010;3:41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas: a case report.
  • Adenosquamous carcinoma of the pancreas is a rare variant of pancreatic exocrine carcinoma.
  • Histological evaluation of the pancreatic tumor showed an adenosquamous carcinoma which was extensively infiltrative with perineural invasion, involvement of peripancreatic lymph nodes and all the thickness of the duodenum wall.
  • The tumor exhibited a biphasic malignant growth identified as well to moderate differentiated adenocarcinoma and well to poorly differentiated squamous cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2008 Sep;207(3):368-70 [18722942.001]
  • [Cites] Digestion. 2005;72(2-3):104-8 [16172546.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):987-90 [16126885.001]
  • [Cites] J Gastroenterol. 2003;38(12):1171-5 [14714256.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1464-84 [10579989.001]
  • [Cites] Int J Pancreatol. 2001;29(1):53-8 [11558633.001]
  • [Cites] Mod Pathol. 2001 May;14(5):443-51 [11353055.001]
  • [Cites] Abdom Imaging. 2000 Jul-Aug;25(4):420-3 [10926197.001]
  • [Cites] Arch Pathol Lab Med. 2000 Feb;124(2):212-5 [10656728.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):372-8 [14681946.001]
  • (PMID = 20205828.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2825199
  •  go-up   go-down


81. Jamali M, Serra S, Chetty R: Adenosquamous carcinoma of the pancreas with clear cell and rhabdoid components. A case report. JOP; 2007;8(3):330-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas with clear cell and rhabdoid components. A case report.
  • CONTEXT: In as much as no such variant of this pancreatic tumour has been previously reported in the literature, we report an unusual case of an adenosquamous carcinoma of the pancreas characterized by clear cells and rhabdoid cells.
  • Endoscopic retrograde pancreatography showed mild to moderate dilatation of the intrapancreatic biliary tract and of the pancreatic duct, and a biliary stent was placed.
  • Histological evaluation of the pancreatic mass revealed an adenosquamous carcinoma displaying both clear cell and rhabdoid components.
  • CONCLUSIONS: Assessing the predominant histology of pancreatic adenosquamous carcinoma variants such as those characterized by clear cells and rhabdoid cells may help select and improve upon therapies in this aggressive lesion.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Pancreatic Neoplasms / pathology. Rhabdoid Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495363.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


82. Imadome K, Iwakawa M, Nakawatari M, Fujita H, Kato S, Ohno T, Nakamura E, Ohkubo Y, Tamaki T, Kiyohara H, Imai T: Subtypes of cervical adenosquamous carcinomas classified by EpCAM expression related to radiosensitivity. Cancer Biol Ther; 2010 Nov 15;10(10):1019-26
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtypes of cervical adenosquamous carcinomas classified by EpCAM expression related to radiosensitivity.
  • Adenosquamous carcinoma (ASC) is a relatively uncommon histological subtype of cervical cancer (CC).
  • A point of controversy is the relative prognosis of ASC compared to squamous cell carcinoma (SCC).
  • All adenocarcinoma (AC) patients were classified into one cluster, and most SCC patients fell into the other cluster.
  • In addition, the inhibition of EpCAM expression using siRNA significantly increased radiation-induced cell death in the cervical cell line, ME-180.
  • [MeSH-major] Adenocarcinoma / classification. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Adenosquamous / classification. Carcinoma, Squamous Cell / classification. Cell Adhesion Molecules / metabolism. Radiation Tolerance / genetics. Uterine Cervical Neoplasms / classification


83. Faria GR, Eloy C, Preto JR, Costa EL, Almeida T, Barbosa J, Paiva ME, Sousa-Rodrigues J, Pimenta A: Primary gastric adenosquamous carcinoma in a Caucasian woman: a case report. J Med Case Rep; 2010;4:351

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric adenosquamous carcinoma in a Caucasian woman: a case report.
  • Primary gastric adenosquamous carcinoma is a rare malignancy, mostly associated with Asian populations.
  • It constitutes less than one percent of all gastric carcinomas and its clinical presentation is the same as adenocarcinoma.
  • It occurs more frequently in the proximal stomach, usually presents with muscular layer invasion and tends to be found in advanced stages at diagnosis, with a worse prognosis than adenocarcinoma.
  • CASE PRESENTATION: We report the case of an 84-year-old Caucasian woman with an adenosquamous carcinoma extending to her serosa with lymphatic and venous invasion (T3N1M1).
  • Nodal and hepatic metastasis presented with both cellular types, with dominance of the squamous component.
  • CONCLUSIONS: Adenosquamous gastric cancer is a rare diagnosis in western populations.
  • We present the case of a woman with a very aggressive adenosquamous carcinoma with a preponderance of squamous cell component in the metastasis.
  • Several origins have been proposed for this kind of carcinoma; either evolution from adenocarcinoma de-differentiation or stem cell origin might be possible.
  • The hypothesis that a particular histological type of gastric cancer may arise from stem cells might be a field of research in oncological disease of the stomach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21034475.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2984469
  •  go-up   go-down


84. Yoshida T, Sano T, Oyama T, Kanuma T, Fukuda T: Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma. Virchows Arch; 2009 Sep;455(3):253-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma.
  • Adenosquamous carcinoma of the uterine cervix is a rare mixture of malignant squamous and glandular epithelial elements and accounts for approximately 10% of cervical carcinomas.
  • The aims of the present study were to evaluate the prevalence, physical status, and viral load of HPV 16 and 18 in adenosquamous carcinoma.
  • Formalin-fixed paraffin-embedded tissue samples from 20 cases of histologically diagnosed adenosquamous carcinoma were examined.
  • The squamous and glandular components were separately microdissected and analyzed for their HPV DNA subtype, viral load, and physical status using real-time polymerase chain reaction (PCR).
  • The percentages of HPV 16- and 18-positive cases among all the HPV-positive cases were 36.8% (7/19) and 57.9% (11/19) in the squamous epithelial elements and 33.3% (6/18) and 61.1% (11/18) in the glandular elements, respectively.
  • The mean HPV 16 DNA copy numbers/cell was 7.22 in the squamous elements and 1.33 in the glandular elements (p=0.04) while the corresponding mean HPV 18 DNA copy numbers/cell was 1.50 and 0.89, respectively.
  • The prevalence of HPV 18 in adenosquamous carcinoma was high and many HPV 18-positive cases were the pure integrated form resulting in very low copy numbers/cell.
  • [MeSH-major] Carcinoma, Adenosquamous / virology. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727809.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


85. Shin JU, Jung JT, You SS, Kwon JG, Kim EY, Lee CH, Kim HG, Park JB: [A case of primary adenosquamous carcinoma of the liver with formation of colonic fistula]. Korean J Gastroenterol; 2006 Nov;48(5):360-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary adenosquamous carcinoma of the liver with formation of colonic fistula].
  • Primary adenosquamous carcinoma of the liver is generally considered as an extremely rare subtype of cholangiocarcinoma.
  • Recently, we experienced a case of primary adenosquamous carcinoma of liver with a formation of tumor-colonic fistula.
  • Colonoscopic examination showed a large colonic wall defect in hepatic flexure and a friable, nodular mucosa around the defected colonic wall.
  • Microscopically, the tumor was composed of squamous cell carcinoma mainly with foci of the adenocarcinoma component.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Colonic Diseases / pathology. Intestinal Fistula / pathology. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17132926.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


86. Kothari RK, Ghosh A, Bhattacharyya SK, Ghosh SK: Adenosquamous carcinoma of oral cavity: a case report. J Indian Med Assoc; 2007 Sep;105(9):531-2
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of oral cavity: a case report.
  • Histopathological examination of the biopsied material showed features suggestive of adenosquamous carcinoma, but CT-guided fine needle aspiration cytology from lung mass showed evidence of non-keratinising squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Mouth Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338480.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


87. Cassarino DS, Derienzo DP, Barr RJ: Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification--part two. J Cutan Pathol; 2006 Apr;33(4):261-79
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification--part two.
  • Cutaneous squamous cell carcinoma (SCC) includes many subtypes with widely varying clinical behaviors, ranging from indolent to aggressive tumors with significant metastatic potential.
  • Therefore, we have proposed the following based upon the malignant potential of SCC variants, separating them into categories of low (< or = 2% metastatic rate), intermediate (3-10%), high (greater than 10%), and indeterminate behavior.
  • Low-risk SCCs include SCC arising in actinic keratosis, HPV-associated SCC, tricholemmal carcinoma, and spindle cell SCC (unassociated with radiation).
  • Intermediate-risk SCCs include adenoid (acantholytic) SCC, intraepidermal epithelioma with invasion, and lymphoepithelioma-like carcinoma of the skin.
  • High-risk subtypes include de novo SCC, SCC arising in association with predisposing factors (radiation, burn scars, and immunosuppression), invasive Bowen's disease, adenosquamous carcinoma, and malignant proliferating pilar tumors.
  • The indeterminate category includes signet ring cell SCC, follicular SCC, papillary SCC, SCC arising in adnexal cysts, squamoid eccrine ductal carcinoma, and clear-cell SCC.
  • [MeSH-major] Carcinoma, Squamous Cell / classification. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / classification. Skin Neoplasms / pathology
  • [MeSH-minor] Dermatology / methods. Diagnosis, Differential. Humans. Neoplastic Processes. Pathology, Surgical / methods. Risk Factors


88. Cassarino DS, Derienzo DP, Barr RJ: Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part one. J Cutan Pathol; 2006 Mar;33(3):191-206
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part one.
  • Cutaneous squamous cell carcinoma (SCC) includes many subtypes with widely varying clinical behaviors, ranging from indolent to aggressive tumors with significant metastatic potential.
  • Therefore, we have proposed the following based upon the malignant potential of SCC variants, separating them into categories of low (< or = 2% metastatic rate), intermediate (3-10%), high (greater than 10%), and indeterminate behavior.
  • Low-risk SCCs include SCC arising in actinic keratosis, HPV-associated SCC, tricholemmal carcinoma, and spindle cell SCC (unassociated with radiation).
  • Intermediate-risk SCCs include adenoid (acantholytic) SCC, intraepidermal epithelioma with invasion, and lymphoepithelioma-like carcinoma of the skin.
  • High-risk subtypes include de novo SCC, SCC arising in association with predisposing factors (radiation, burn scars, and immunosuppression), invasive Bowen's disease, adenosquamous carcinoma, and malignant proliferating pilar tumors.
  • The indeterminate category includes signet ring cell SCC, follicular SCC, papillary SCC, SCC arising in adnexal cysts, squamoid eccrine ductal carcinoma, and clear-cell SCC.
  • [MeSH-major] Carcinoma, Squamous Cell / classification. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / classification. Skin Neoplasms / pathology
  • [MeSH-minor] Dermatology / methods. Diagnosis, Differential. Humans. Neoplastic Processes. Pathology, Surgical / methods. Risk Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466506.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 234
  •  go-up   go-down


89. Ueda Y, Miyatake T, Okazawa M, Kimura T, Miyake T, Fujiwara K, Yoshino K, Nakashima R, Fujita M, Enomoto T: Clonality and HPV infection analysis of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix. Am J Clin Pathol; 2008 Sep;130(3):389-400
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonality and HPV infection analysis of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix.
  • We analyzed the clonality and human papillomavirus (HPV) infection status of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix to clarify their histogenesis.
  • The glandular and squamous components were clonally different from each other in 7 informative concurrent lesions.
  • HPV was episomal in 2 polyclonal glandular dysplasias (GDs).
  • HPV was in a mixed integrated-episomal form in a monoclonal GD, an adenocarcinoma in situ, and an adenocarcinoma.
  • Both tumor components were monoclonal in origin in 6 adenosquamous carcinomas, with identical patterns of X-chromosomal inactivation and types and physical status of HPV.
  • These results imply that the concurrent glandular and squamous lesions are formed separately, whereas adenosquamous carcinoma is more likely to be a combination tumor of monoclonal origin, and that integration of HPV has an important role in the progression from polyclonal GD through monoclonal expansion to adenocarcinoma in situ and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / virology. Cervix Uteri / pathology. Cervix Uteri / virology. Endometrial Neoplasms / virology. Papillomavirus Infections / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701412.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


90. Martinho O, Gonçalves A, Moreira MA, Ribeiro LF, Queiroz GS, Schmitt FC, Reis RM, Longatto-Filho A: KIT activation in uterine cervix adenosquamous carcinomas by KIT/SCF autocrine/paracrine stimulation loops. Gynecol Oncol; 2008 Nov;111(2):350-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT activation in uterine cervix adenosquamous carcinomas by KIT/SCF autocrine/paracrine stimulation loops.
  • OBJECTIVES: Uterine adenosquamous carcinoma (ASC) is an uncommon, yet, one of the most aggressive cervical cancer subtype.
  • METHODS: In a series of 30 cases, we studied KIT (CD117), KIT phosphorylated/activated form, as well as KIT ligand, stem cell factor (SCF), by immunohistochemistry.
  • [MeSH-major] Carcinoma, Adenosquamous / enzymology. Proto-Oncogene Proteins c-kit / metabolism. Stem Cell Factor / metabolism. Uterine Cervical Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18708242.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Stem Cell Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


91. Cooke DT, Nguyen DV, Yang Y, Chen SL, Yu C, Calhoun RF: Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy. Ann Thorac Surg; 2010 Sep;90(3):943-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy.
  • BACKGROUND: Primary adenosquamous carcinoma (ASC) of the lung is a rare tumor that may carry a poor prognosis.
  • We examined a national database to see if ASC exhibited distinct clinical behavior from squamous cell (SC) and adenocarcinoma (AC) of the lung.
  • Analysis characterized clinical variables to determine patterns of presentation and compared survival among the above three histologic groups after lobectomy for stage I and II disease.
  • Survival after lobectomy for stage I and II disease was significantly reduced in ASC and SC compared with AC (p < 0.0001).
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / mortality. Lung Neoplasms / surgery. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20732522.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024146
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


92. Okabayashi K, Hasegawa H, Ishii Y, Endo T, Kitagawa Y: Adenosquamous carcinoma of the sigmoid colon treated by the less invasive procedures of endoscopy and laparoscopy: report of a case. Surg Today; 2009;39(11):994-7
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the sigmoid colon treated by the less invasive procedures of endoscopy and laparoscopy: report of a case.
  • A 51-year-old man demonstrated a positive finding for a fecal occult blood test during a screening examination.
  • Total colonoscopy was therefore performed, and a semi-pedunculated polyp was detected in the sigmoid colon.
  • Although this polyp was suspected of invading the submucosal layer, it was removed endoscopically because the preoperative diagnosis was well-differentiated adenocarcinoma.
  • The pathological findings revealed adenosquamous carcinoma that had invaded the submucosal layer with lymphatic invasion.
  • A laparoscopic bowel resection was then performed and a histopathological examination of the surgical specimen showed metastasis to two regional lymph nodes.
  • Adenosquamous carcinoma has been reported to be rare and to possess a highly metastatic potential.
  • It consists of both squamous cells and glandular cell components.
  • We report a case of adenosquamous carcinoma of the sigmoid colon treated by less invasive approaches consisting of an endoscopic mucosal resection and a subsequent laparoscopic colectomy.
  • [MeSH-major] Carcinoma, Adenosquamous / surgery. Colectomy / methods. Colon, Sigmoid / surgery. Colonoscopy / methods. Laparoscopy / methods. Sigmoid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882324.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


93. Ma K, Wang TY, He BL, Chang D, Gong M: [Impact of different mediastinal lymphadenectomy on clinical-stage IA non-small cell lung cancer]. Zhonghua Wai Ke Za Zhi; 2008 May 1;46(9):670-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of different mediastinal lymphadenectomy on clinical-stage IA non-small cell lung cancer].
  • OBJECTIVE: To study the role of different lymphadenectomy in the treatment of selected clinical-stage IA non-small cell lung cancer.
  • METHODS: All 115 postoperative patients admitted from January 1997 to May 2002 with pathologic-stage T1 who had been preoperatively diagnosed as clinical-stage I A non-small cell lung cancer were divided into a radical systematic mediastinal lymphadenectomy (LA) group and a mediastinal lymph node sampling (LS) group.
  • Impacts on morbidity, N staging, overall survival (OS) and disease-free survival (DFS) were evaluated in each group respectively.
  • In addition, patients with large cell carcinoma and adenosquamous carcinoma were associated with significantly poor 5-year OS (P < 0.05) , and patients with lymph node metastases were associated with poor 5-year OS as well as 5-year DFS (P < 0.01).
  • CONCLUSIONS: After being intraoperatively identified as T1 stage, patients with lesions of more than 2 cm in clinical-stage IA non-small cell lung cancer should be performed with LA to get a better survival, and patients with lesions of 2 cm or less should be performed with LS to decrease invasion.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Lymph Node Excision / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956719.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


94. Vietharsdóttir H, Moeller PH, Jóhannsson J, Jónasson JG: [Anal cancer in Iceland 1987-2003. A population based study]. Laeknabladid; 2006 May;92(5):365-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carcinoma ani á Islandi 1987-2003 -- lýethgrundueth rannsókn.
  • OBJECTIVE: Anal cancer is a rare disease.
  • MATERIAL AND METHODS: This is a retrospective study in which all malignant anal tumours diagnosed in Iceland in the period 1987-2003 were reviewed with respect to patient outcome.
  • This is a nationwide, population-based study of malignant tumours of the anal region.
  • The average age at diagnosis was 63.4 years.
  • Most patients had squamous cell carcinoma (n=30).
  • The remaining histologic types were malignant melanoma (n=3), adenosquamous carcinoma (n=1), adenocarcinoma (n=1), GIST (n=1) and undifferentiated carcinoma (n=2).
  • The duration of symptoms before diagnosis ranged from 2 weeks to 96 months (mean value 3.5 months).
  • The mean value of the time from diagnosis of the primary to the recurrent cancer was 15.6 months (range, 5.9-117).
  • Sixteen patients remain with disease and ten have died of anal cancer.
  • Average age at diagnosis, male-female ratio and prognosis is similar to reports in other studies.
  • The proportion of adenocarcinoma of the anus is lower in Iceland than elsewhere.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Defecation. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iceland / epidemiology. Incidence. Male. Melanoma / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pain / etiology. Pruritus / epidemiology. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741319.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


95. Bastide K, Ugolin N, Levalois C, Bernaudin JF, Chevillard S: Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level? Lung Cancer; 2010 Apr;68(1):1-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level?
  • Adenocarcinomas (AC), squamous cell carcinomas (SCC) and adenosquamous carcinomas (ASC) are three histological subtypes of non-small-cell lung carcinomas (NSCLC).
  • ASC are morphologically mixed tumours that contain the two cell components AC and SCC.
  • In conclusion, the ASC mixed lung tumours are more complex than simple mixes of AC and SCC components.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Adenosquamous / genetics. Carcinoma, Squamous Cell / genetics. Lung / metabolism. Lung Neoplasms / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Transformation, Neoplastic. DNA Mutational Analysis. GATA6 Transcription Factor / genetics. GATA6 Transcription Factor / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, ras / genetics. MAP Kinase Signaling System / genetics. Microarray Analysis. Mucin-1 / genetics. Mucin-1 / metabolism. Radon / toxicity. Rats. Rats, Sprague-Dawley. Receptor, Notch2 / genetics. Receptor, Notch2 / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. RADON, RADIOACTIVE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20004040.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / GATA6 Transcription Factor; 0 / Gata6 protein, rat; 0 / Mucin-1; 0 / Receptor, Notch2; Q74S4N8N1G / Radon
  • [Number-of-references] 61
  •  go-up   go-down


96. Ma QL, Liu DR, Guo YQ, Shi B, Song ZY, Tian YC: [Prognostic analysis of N2 non-small cell lung cancer]. Zhonghua Wai Ke Za Zhi; 2009 Jul 15;47(14):1058-60
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of N2 non-small cell lung cancer].
  • OBJECTIVE: To evaluate the surgical therapeutic strategy and prognostic factors for non-small cell lung cancer (NSCLC) with mediastinal lymph node metastasis (N2).
  • The procedure of operation (lobectomy, pneumonectomy and palliative resection), histological classification (squamous cell carcinoma, adenocarcinoma, mixed carcinoma, and large cell carcinoma and others), T primary tumor status, and adjuvant therapy were analyzed to determine their impact on the 5-year survival rate.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781268.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


97. Ohtsuka K, Ohnishi H, Fujiwara M, Kishino T, Matsushima S, Furuyashiki G, Takei H, Koshiishi Y, Goya T, Watanabe T: Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer; 2007 Feb 15;109(4):741-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
  • BACKGROUND: Tyrosine kinase domain (TKD) gene mutations of the epidermal growth factor receptor gene (EGFR) have proven to be clinically significant in nonsmall-cell lung cancer (NSCLC), particularly in adenocarcinoma.
  • However, TKD mutations together with deletion mutations in the extracellular domain of EGFR (EGFRvIII) have not been fully investigated in NSCLC except for adenocarcinoma.
  • METHODS: EGFR TKD mutations were investigated using direct sequencing and mutation-specific polymerase chain reaction (PCR), and EGFRvIII mutations were examined using reverse transcriptase-PCR in samples from 42 NSCLC patients and 6 NSCLC cell lines excluding adenocarcinoma.
  • RESULTS: EGFR TKD mutations were detected in 1 of 7 (14%) squamous-cell carcinomas with an adenocarcinoma component and 2 of 4 (50%) adenosquamous carcinomas.
  • In contrast, EGFR TKD mutations were not identified in 24 pure squamous-cell carcinomas without any adenocarcinoma component, 7 large-cell carcinomas, or 6 cell lines.
  • EGFRvIII was detected solely in 1 of 7 large-cell carcinomas (14%), but not in 31 squamous-cell carcinomas, 4 adenosquamous carcinomas, or 6 cell lines.
  • CONCLUSIONS: These results suggest that EGFR TKD mutations are found in NSCLCs with an adenocarcinoma element.
  • [MeSH-major] Carcinoma, Adenosquamous / genetics. Carcinoma, Large Cell / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17238183.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / epidermal growth factor receptor VIII; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


98. Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Bronson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG, Solca F, Wistuba II, Wong KK: HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A; 2009 Jan 13;106(2):474-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
  • Here we demonstrate that inducible expression of the most common HER2 mutant (HER2(YVMA)) in mouse lung epithelium causes invasive adenosquamous carcinomas restricted to proximal and distal bronchioles.
  • Continuous expression of HER2(YVMA) is essential for tumor maintenance, suggesting a key role for HER2 in lung adenosquamous tumorigenesis.
  • Based on these findings, clinical testing of the BIBW2992/rapamycin combination in non-small cell lung cancer patients with tumors expressing HER2 mutations is warranted.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2004 Sep 30;431(7008):525-6 [15457249.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1 Suppl 1):75-82 [14981584.001]
  • [Cites] Cell. 1989 Jul 28;58(2):287-92 [2568888.001]
  • [Cites] Oncogene. 1991 Jul;6(7):1189-94 [1713661.001]
  • [Cites] AJR Am J Roentgenol. 1994 Aug;163(2):301-6 [8037019.001]
  • [Cites] EMBO J. 1997 Apr 1;16(7):1647-55 [9130710.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1642-6 [15753357.001]
  • [Cites] Cancer. 2005 May 1;103(9):1865-73 [15770690.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):485-95 [16730237.001]
  • [Cites] Cancer Cell. 2006 Jul;10(1):25-38 [16843263.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4372s-4376s [16857813.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7242-51 [17189395.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):81-93 [17613438.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5023-7 [17311002.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4702-11 [18408761.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] EMBO J. 2001 Apr 2;20(7):1726-38 [11285236.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3249-62 [11751631.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 4):59-65 [11894015.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):495-505 [12620236.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):19-27 [14679114.001]
  • [Cites] Trends Mol Med. 2004 Oct;10(10):481-6 [15464447.001]
  • (PMID = 19122144.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / R01 CA122794; United States / NCI NIH HHS / CA / P20 CA90578; United States / NCI NIH HHS / CA / R01 CA90687; United States / NIA NIH HHS / AG / R01 AG2400401; United States / NCI NIH HHS / CA / R01 CA090687
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIBW 2992; 0 / Quinazolines; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC2626727
  •  go-up   go-down


99. Chan KM, Yu MC, Lee WC, Jan YY, Chen MF: Adenosquamous/squamous cell carcinoma of the gallbladder. J Surg Oncol; 2007 Feb 1;95(2):129-34
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous/squamous cell carcinoma of the gallbladder.
  • BACKGROUND AND OBJECTIVES: Adenosquamous/squamous cell carcinoma is a rare histopathologic subtype of gallbladder malignancy.
  • Its clinical features have rarely been described, and its differences from the major histopathologic subtype, adenocarcinoma, remain uncertain.
  • METHODS: All patients with gallbladder carcinoma were retrospectively reviewed.
  • Patients with a histopathologic subtype of either adenosquamous (n = 12) or squamous cell (n = 2) carcinoma were categorized to group I, and patients with adenocarcinoma were categorized to group II.
  • CONCLUSIONS: Patients with adenosquamous/squamous cell carcinoma of the gallbladder were generally similar to those with adenocarcinoma in clinical characteristics, but had a tendency for liver infiltration.
  • Although the two histopathologic subtypes of the gallbladder carcinoma had similar poor outcomes, better survival could be obtained by performing curative resection for these patients.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / surgery. Gallbladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17262729.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Takahashi K, Hirano F, Matsumoto K, Aso K, Haneda M: Homeobox gene CDX2 inhibits human pancreatic cancer cell proliferation by down-regulating cyclin D1 transcriptional activity. Pancreas; 2009 Jan;38(1):49-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homeobox gene CDX2 inhibits human pancreatic cancer cell proliferation by down-regulating cyclin D1 transcriptional activity.
  • This study is intended to investigate the effect of CDX2 expression on cell proliferation and cyclin D1 expression in pancreatic cancer cells.
  • METHODS: Four pancreatic ductal adenocarcinoma cell lines (PancQGO-1, BxPC-3, MIAPaCa-2, CFPAC-1), 1 islet carcinoma cell line (QGP-1), and 1 adenosquamous carcinoma cell line (KP-3) were analyzed for CDX1 and CDX2 expression using real-time reverse transcription-polymerase chain reaction and Western blot analysis.
  • Moreover, CDX2 was expressed at a middle level in 4 pancreatic ductal adenocarcinoma cells.
  • Cell proliferation and cyclin D1 mRNA level were inhibited significantly after CDX2 transfection in pancreatic cancer cells.
  • CONCLUSIONS: CDX2 might play a role in inhibiting cell proliferation and repressing cyclin D1 transcriptional activity through the proximal nuclear factor kappaB binding site in pancreatic cancer cells.
  • [MeSH-major] Cell Proliferation. Cyclin D1 / genetics. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Pancreatic Neoplasms / genetics. Transcription, Genetic
  • [MeSH-minor] Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Islet Cell / genetics. Carcinoma, Islet Cell / pathology. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / pathology. Cell Line, Tumor. Cyclooxygenase 2 / genetics. Down-Regulation. Humans. NF-kappa B / genetics. Promoter Regions, Genetic. RNA, Messenger / metabolism. Time Factors. Transfection

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106744.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / CDX1 protein, human; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / NF-kappa B; 0 / RNA, Messenger; 136601-57-5 / Cyclin D1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down






Advertisement